

# Bibliographie

- Abbott, F. M. (2016), «Excessive Pharmaceutical Prices and Competition Law: Doctrinal Development to Protect Public Health», *UC Irvine Law Review* 6(3), pages 281 à 320.
- Abbott, F. M. et Correa, C. M. (2007), «World Trade Organization Accession Agreements: Intellectual Property Issues», Law, Business and Economics Paper, FSU College of Law (faculté de droit de la Florida State University), Quaker United Nations Office (Bureau Quaker auprès des Nations Unies), Genève.
- Abbott, F. M. et Reichman, J. H. (2007), «The Doha Round's public health legacy: Strategies for the production and diffusion of patented medicines under the amended TRIPS provisions», *Journal of International Economic Law* 10(4), pages 921 à 987.
- Aboy, M., Crespo, C., Liddell, K., Liddicoat, J. et Jordan, M. (2018), «Was the *Myriad* decision a surgical strike on isolated DNA patents, or does it have wider impacts?», *Nature Biotechnology*, n° 36, pages 1146 à 1149.
- Adlung, R. (2009), «Services Liberalization from a WTO/GATS Perspective: In Search of Volunteers», document de travail ERSD–2009–05, OMC, Genève.
- Adlung, R. (2010), «Trade in healthcare and health insurance services: WTO/GATS as a supporting actor(?)», *Intereconomics* 45(4), pages 227 à 238.
- Agence des médicaments et des produits alimentaires des États-Unis (FDA) (2017a), «FDA approval brings first gene therapy to the United States», communiqué de presse, voir: <https://www.fda.gov/news-events/press-announcements/fda-approval-brings-first-gene-therapy-united-states>.
- Agence des médicaments et des produits alimentaires des États-Unis (FDA), «FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss, press announcement», voir: <https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss>.
- Agence des médicaments et des produits alimentaires des États-Unis (FDA) (2018), «FDA approves first generic version of EpiPen», communiqué de presse voir: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-version-epipen>.
- Agence des médicaments et des produits alimentaires des États-Unis (FDA) (2019a), *Advancing Health through Innovation: 2018 New Drug Therapy Approvals*, voir: <https://www.fda.gov/media/120357/download>.
- Agence des médicaments et des produits alimentaires des États-Unis (FDA) (2019b), *Considerations in Demonstrating Interchangeability with a Reference Product: Guidance for Industry*, FDA, Washington (D.C.).
- Aitken, M. et Kleinrock, M. (2017), *Lifetime Trends in Biopharmaceutical Innovation: Recent Evidence and Implications*, IQVIA Institute for Human Data Science, Parsippany (New Jersey).
- Albrecht, B., Menu, P., Tsao, J. et Webster, K. (2016), *The Next Wave of Innovation in Oncology*, McKinsey & Company, voir: <https://www.mckinsey.com/~media/McKinsey/Industries/Healthcare%20Systems%20and%20Services/Our%20Insights/The%20next%20wave%20of%20innovation%20in%20oncology/The-next-wave-of-innovation-in-oncology.ashx>.
- Ali, F., Rajagopal, S., Mustafa, M. et Prabhu, C. (2017), *Rejected in India: What the Indian Patent Office Got Right on Pharmaceuticals Patent Applications (2009-2016)*, voir: <https://www.accessibsa.org/media/2017/12/Rejected-in-India.pdf>.
- Allee, T. et Peinhardt, C. (2011), «Contingent Credibility: The Impact of Investment Treaty Violations on Foreign Direct Investment», *International Organization Journal* 65(3), pages 401 à 432.
- Amanam, I. U., Gardner, A. B., Young-Lin, N. et Chan, J. K. (2016), «The increase in FDA-approved novel cancer drugs over the last 5 years: What factors are involved?», *Journal of Clinical Oncology* 34(15), page e14111.
- Anderson, R. (2014), «Pharmaceutical industry gets high on fat profits», *BBC News*, version en ligne, 6 novembre 2014, voir: <https://www.bbc.com/news/business-28212223>.
- Anderson, R. D., Kovacic, W. E. et Müller, A. C. (2011), «Ensuring Integrity and Competition in Public Procurement Markets: A Dual Challenge for Good Governance», dans Arrowsmith, S. et Anderson, R. D. (éds), *The WTO Regime on Government Procurement: Challenge and Reform*, Cambridge University Press, Cambridge.
- Anderson, R. D., Kovacic, W. E., Müller, A. C. et Sporysheva, N. (2018), «Competition Policy, Trade and the Global Economy: Existing WTO Elements, Commitments in Regional Trade Agreements, Current Challenges and Issues for Reflection», document de travail ERSD 2018-12, OMC, Genève.
- Anderson, R. D., Müller, A. C. et Pelletier, P. (2016), «Regional Trade Agreements and Procurement Rules: Facilitators or Hindrances?» Une version a été publiée en tant que document de recherche du Robert Schuman Centre for Advanced Studies (RSCAS), n° RSCAS 2015/81, décembre 2015.
- Anderson, R. D., Pires de Carvalho, N. et Taubman, A. (éds) (2020), *Competition Policy and Intellectual Property in Today's Global Economy*, Cambridge University Press, Cambridge.
- Aranze, J. (2017), «Italian court upholds Aspen excessive pricing decision», *Global Competition Review*, 3 août 2017, voir: <https://globalcompetitionreview.com/article/1145288/italian-court-upholds-aspen-excessive-pricing-decision>.
- Årdal, C., Findlay, D., Savic, M., et al. (2018), *Revitalizing the antibiotic pipeline: Stimulating innovation while driving sustainable use and global access*, voir: <http://drive-ab.eu/wp-content/uploads/2018/01/DRIVE-AB-Final-Report-Jan2018.pdf>.
- Armstrong, I. (2019), «Immunotherapy patents: Why CAR-T is driving up patent activity», *World Intellectual Property Review*, version en ligne, 17 septembre 2019.
- Association de lutte contre le sida (2018), *Diagnosis and monitoring of hepatitis C (HCV) in Morocco: Current Status and strategies for universal access*, voir: <https://www.alcs.ma/1282-diagnosis-and-monitoring-of-hepatitis-c-hcv-in-morocco>.
- Association médicale mondiale (AMM) (2013), *Déclaration d'Helsinki de l'AMM – Principes éthiques applicables à la recherche médicale impliquant des êtres humains*.
- Avorn, J. (2015), «The \$2.6 billion pill – Methodologic and policy considerations», *New England Journal of Medicine*, n° 372, pages 1877 à 1879.

- Baghdadi-Sabeti, G. et Serhan, F. (2010), «WHO Good Governance for Medicines Programme: An Innovative Approach to Prevent Corruption in the Pharmaceutical Sector», Rapport sur la santé dans le monde (2010), note d'information n° 25, OMS, Genève.
- Bagley, N., Chandra, A., Garthwaite, C. et Stern, A.D. (2018), «It's Time to Reform the Orphan Drug Act», *NEJM Catalyst*, 19 décembre 2018.
- Balasegaram, M., Kolb, P., McKew, J., Menon, J., Oliaro, P., Sablinski, T., *et al.* (2017), «An open source pharma roadmap», *PLoS Medicine* 14(4), page e1002276.
- Ball, D. (2011), «The Regulation of Mark-ups in the Pharmaceutical Supply Chain», Projet OMS/HAI sur les prix et la disponibilité des médicaments, Examen des interventions et des politiques tarifaires en matière de produits pharmaceutiques, document de travail n° 3, OMS et HAI, Genève.
- Banque mondiale (2005), *A Guide to Competitive Vouchers in Health*, Banque mondiale, Washington (D.C.).
- Banque mondiale (2009), «Europe and Central Asia: Health Insurance and Competition», rapport n° 44316-ECA, Banque mondiale, Washington (D.C.).
- Batson, A. (2016), *Global vaccine market*, Global Vaccine and Immunization Research Forum, mars 2016, voir: [https://www.who.int/immunization/research/forums\\_and\\_initiatives/1\\_ABatson\\_Global\\_Vaccine\\_Market\\_gvirf16.pdf](https://www.who.int/immunization/research/forums_and_initiatives/1_ABatson_Global_Vaccine_Market_gvirf16.pdf).
- Beall, R. F. et Attaran, A. (2016), *Global Challenges Report: Patent-based Analysis of the World Health Organization's 2013 Model List of Essential Medicines*, OMPI, Genève.
- Beall, R. F. et Kesselheim, A. S. (2018), «Tertiary patenting on drug-device combination products in the United States», *Nature Biotechnology*, n° 36, pages 142 à 145.
- Beall, R. F., Darrow, J. J. et Kesselheim, A. S. (2019), «Patent term restoration for top-selling drugs in the United States», *Drug Discovery Today* 24(1), pages 20 à 25.
- Beall, R. F., Nickerson, J. W., Kaplan, W. A. et Attaran, A. (2016), «Is patent 'evergreening' restricting access to medicine/device combination products?», *PLoS ONE* 11(2), page e0148939.
- Ben-Ayre, E., Schiff, E., Hassan, E., Mutafoğlu, K., Lev-Ari, S., Steiner, M. *et al.* (2012), «Integrative oncology in the Middle East: From traditional herbal knowledge to contemporary cancer care», *Annals of Oncology* 23(1), pages 211 à 221.
- Bennett, M. R. (1999), «One hundred years of adrenaline: The discovery of autoreceptors», *Clinical Autonomic Research* 9(3), pages: 145 à 159.
- Beran, D., Ewen, M. et Laing, R. (2016), «Constraints and challenges in access to insulin: A global perspective», *The Lancet Diabetes and Endocrinology* 4(3), pages 275 à 285.
- Berndt, E. et Aitken, M. (2011), «Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation», *International Journal of the Economics of Business* 18(2), pages 177 à 201.
- Bertram, M. Y., Lauer, J. A., De Joncheere, K., Edejer, T., Hutubessy, R. Kieny, M.-P. *et al.* (2016), «Seuils de rentabilité: avantages et inconvénients», *Bulletin de l'Organisation mondiale de la Santé* 94(12), pages 925 à 930.
- Beyer, P. (2012), «Developing Socially Responsible Intellectual Property Licensing Policies: Non-Exclusive Licensing Initiatives in the Pharmaceutical Sector», dans de Werra, J. (éd.), *La propriété intellectuelle dans l'industrie pharmaceutique: Intellectual Property in the Pharmaceutical Industry*, Schulthess Verlag, Genève.
- Black, L. L. (2017), «Patenting and protecting personalized medicine innovation post-Mayo, Myriad, and Limelight», *North Carolina Law Review* 95(2), pages 493 à 522.
- Blackstone, E. A. et Fuhr, J. P. (2013), «The economics of biosimilars», *American Health & Drug Benefits* 6(8), pages 469 à 478.
- Bloom, N., Jones, C. I., Van Reenen, J. et Webb, M. (2017), «Are Ideas Getting Harder to Find?», document de travail n° w23782, National Bureau of Economic Research (NBER), Cambridge (Massachusetts).
- Bond, R. S. and Lean, D. F. (1977), *Sales, Promotion, and Product Differentiation in Two Prescription Drug Markets: Staff Report to the Federal Trade Commission*, Washington, DC: Federal Trade Commission.
- Bosco, J. et Chance, K. (2013), «Biosimilars: Stakeholders' Changing Expectations and the Role of Real-World Evidence», présentation en ligne, Quintiles.
- Bowers, S. et Cohen, D. (2018), «How lobbying blocked European safety checks for dangerous medical implants», *BMJ*, n° 363, page k4999.
- Brazil, R. (2018), «Navigating Drug Discovery with High-Throughput Screening», *Drug Discovery*, version en ligne, 21 février 2018, voir: <https://www.technologynetworks.com/drug-discovery/articles/navigating-drug-discovery-with-high-throughput-screening-297350>.
- Bregonje, M. (2005), «Patents: A unique source for scientific technical information in chemistry related industry?», *World Patent Information* 27(4), pages 309 à 315.
- Brett, A. S. (2010), «Spotlight on colchicine: The Colcrys controversy», *NEJM Journal Watch*.
- Brigden, G., Castro, J. L., Ditiu, L., Gray, G., Hanna, D., Low, M. *et al.* (2017), «Tuberculosis and antimicrobial resistance – new models of research and development needed», *Bulletin de l'Organisation mondiale de la Santé* 95(5), page 315.
- Brigden G., Hewison, C. et Varaine, F. (2015), «New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid», *Infection and Drug Resistance*, n° 8, pages 367 à 378.
- Bud, R. (2008), «Upheaval in the moral economy of science? Patenting, teamwork and the World War II experience of penicillin», *History and Technology*, n° 24, pages 173 à 190.
- Budish, E., Roin, B. N. et Williams, H. (2015), «Do firms underinvest in long-term research? Evidence from cancer clinical trials», *American Economic Review* 105(7), pages 2044 à 2085.
- Bureau du Haut-Commissariat des Nations Unies aux droits de l'homme (HCDH) et Organisation mondiale de la Santé (OMS) (2008), «Le droit à la santé», Fiche d'information n° 31, HCDH et OMS, Genève.
- Cameron, A. et Laing, R. (2010), «Cost Savings of Switching Private Sector Consumption from Originator Brand Medicines to Generic Equivalents», Rapport sur la santé dans le monde (2010), note d'information n° 35, OMS, Genève.

- Cameron, A., Ewen, N., Ross-Degnan, D., Ball, D. et Laing, R. (2009), «Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis», *The Lancet*, n° 373(9659), pages 240 à 249.
- Cameron, A., Roubos, I., Ewen, M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M. et Laing, R. O. (2011), «Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries», *Bulletin de l'Organisation mondiale de la Santé* 89(6), pages 412 à 421.
- Campagne d'accès aux médicaments essentiels (2011), *Untangling the Web of Antiretroviral Price Reductions*, 14<sup>ème</sup> édition, Médecins Sans Frontières, Genève.
- Campagne d'accès MSF (2015), *The Right Shot: Généraliser l'accès à des vaccins plus abordables et mieux adaptés*, 2<sup>ème</sup> édition, Médecins Sans Frontières, Genève.
- Campagne d'accès MSF (2017), *A Fair Shot for Vaccine Affordability: Understanding and Addressing the Effects of Patents on Access to Newer Vaccines*, Médecins Sans Frontières, Genève.
- Capra International Ltd (2016), *Comprehensive Evaluation of the Implementation of the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property: Corporate Evaluation Commissioned by the WHO Evaluation Office*, Capra International et OMS, Cumberland (Ontario).
- Caro de Sousa, P. (2019), «Excessive Pricing in Pharmaceutical Markets», *Competition Policy International*, version en ligne, 20 janvier 2019, voir: <https://www.competitionpolicyinternational.com/excessive-pricing-in-pharmaceutical-markets/>.
- Cassier, M. et Sinding C. (2008), «Patenting in the public interest: administration of insulin patents by the University of Toronto», *History and Technology* 24(2), pages 153 à 171.
- Cassini et al. (2019), «Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis», *The Lancet Infectious Diseases* 19(1), pages 56 à 66, voir: [http://dx.doi.org/10.1016/S1473-3099\(18\)30605-4](http://dx.doi.org/10.1016/S1473-3099(18)30605-4).
- de Chadarevian, S. (2011), «The Making of an Entrepreneurial Science: Biotechnology in Britain, 1975-1995», *Isis* 102(4), pages 601 à 633.
- Chakradhar, S. et Khamsi, R. (2017), «Angst about exclusivity: The potential cost of incentivizing makers of generic drugs», *Nature Medicine* 23(10), pages 1114 à 1116.
- Chandrasekharan S., Amin, T., Kim, J., Furrer, E., et al. «Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing-country vaccine manufacturers», *Vaccine* 33(46), pages 6366 à 6370.
- Chapman, N., Doubell, A., Oversteegen, L., Chowdhary, V., Rugarabamu, G., Zanetti, R. et al. (2017), *G-FINDER 2017: Neglected Disease Research and Development: Reflecting on a Decade of Global Investment*, Policy Cures Research, Sydney.
- Chaudhuri, S., Goldberg, P. K. et Jia, P. (2006), «Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India», *American Economic Review* 96(5), pages 1477 à 1514.
- Cheever, M. A. et Higano, C. S. (2011), «PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine», *Clinical Cancer Research*, n° 17, pages 3520 à 3526.
- Cherny, N., Sullivan, R., Torode, J., Saar, M. et Eniu, A. (2016), «ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe», *Annals of Oncology* 27(8), pages 1423 à 1443.
- Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y. et al. (2017), «ESMO-Magnitude of Clinical Benefit Scale version 1.1», *Annals of Oncology*, n° 28, pages 2340 à 2366.
- Cherny, N. I., Sullivan, R., Torode, J., Saar, M. et Eniu, A. (2017), «ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe», *Annals of Oncology* 28(11), pages 2633 à 2647.
- Chien, C. (2003), «Cheap Drugs at What Price to Innovation: Does the Compulsory Licensing of Pharmaceuticals Hurt Innovation?», *Berkeley Technology Law Journal* 18(3), pages 853 à 907.
- Chopra, R. et Lopes, G. (2017), «Improving access to cancer treatments: The role of biosimilars», *Journal of Global Oncology* 3(5), pages 596 à 610.
- Christie, A.F., Dent, C., McIntyre, P., Wilson, L., et al. (2013), «Patents Associated with High-Cost Drugs in Australia», *PLoS ONE* 8(4), page e60812, voir: <https://doi.org/10.1371/journal.pone.0060812>.
- Cleary, E. G., Beierlein, J. M., Khanuja, N. S., McNamee, L. M. et Ledley, F. D. (2018) «Contribution of NIH funding to new drug approvals 2010-2016», *Proceedings of the National Academy of Sciences of the United States of America* 115(10), pages 2329 à 2334.
- Clendinen, C., Zhang, Y., Warburton, R. N., et Light, D. W. (2016), «Manufacturing costs of HPV vaccines for developing countries», *Vaccine* 34(48), pages 5984 à 5989.
- Cockburn, I. M. (2006), «Is the Pharmaceutical Industry in a Productivity Crisis?», dans Jaffe, A. B., Lerner, J. et Stern, S. (éds), *Innovation Policy and the Economy, Volume 7*, National Bureau of Economic Research (NBER), Cambridge (Massachusetts).
- Cockburn, I. M., Lanjouw, J. O. et Schankerman, M. (2016), «Patents and the global diffusion of new drugs», *American Economic Review* 106(1), pages 136 à 164.
- Cohen, J. (2017), «New CRISPR tool can detect tiny amounts of viruses», *Science*, version en ligne, 13 avril 2017.
- Cohen, W. M., Nelson, R. R. et Walsh, J. P. (2000), «Protecting Their Intellectual Assets: Appropriability Conditions and Why US Manufacturing Firms Patent (or Not)», document de travail n° 7552, National Bureau of Economic Research (NBER), Cambridge (Massachusetts).
- Coller, B.G., Blue, J., Das, R., et al. (2017), «Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic», *Vaccine*, n° 35, pages 4465 à 4469.
- Comanor, W. S. (1986), «The political economy of the pharmaceutical industry», *Journal of Economic Literature* 24(3), pages 1178 à 1217.
- Comanor, W. S. et Scherer, F. M. (2013), «Mergers and innovation in the pharmaceutical industry», *Journal of Health Economics* 32(1), pages 106 à 113.
- Commission européenne (2009a), *Communication de la Commission: Synthèse du rapport d'enquête sur le secteur pharmaceutique*, voir: [https://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/communication\\_fr.pdf](https://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/communication_fr.pdf).

- Commission européenne (2009b), *Pharmaceutical Sector Inquiry: Final Report: Adoption date: 8 July 2009*, disponible en deux parties, voir: <https://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/>.
- Commission européenne (2014a), «Innovation: une société allemande remporte une récompense de 2 millions d'euros offerte par l'UE pour la mise au point d'une technologie dans le domaine des vaccins», communiqué de presse, 10 mars 2014, voir: [https://ec.europa.eu/commission/presscorner/detail/fr/IP\\_14\\_229](https://ec.europa.eu/commission/presscorner/detail/fr/IP_14_229).
- Commission européenne (2014b), *Medical Countermeasures That Could Be Procured in Common Under the Joint Procurement Agreement*, voir: [https://ec.europa.eu/health/sites/health/files/preparedness\\_response/docs/jpa\\_note\\_scope\\_en.pdf](https://ec.europa.eu/health/sites/health/files/preparedness_response/docs/jpa_note_scope_en.pdf).
- Commission européenne (2017), «Pratiques anticoncurrentielles: la Commission ouvre une procédure formelle d'examen sur les pratiques tarifaires d'Aspen Pharma concernant des médicaments contre le cancer», communiqué de presse, 15 mai 2017, voir: [https://ec.europa.eu/commission/presscorner/detail/fr/IP\\_17\\_1323](https://ec.europa.eu/commission/presscorner/detail/fr/IP_17_1323).
- Commission européenne (2018a), *Innovative Payment Models for High-cost Innovative Medicines: Report of the Expert Panel on Effective Ways of Investing in Health (EXPH)*, Office des publications de l'Union européenne, Luxembourg.
- Commission européenne (2018b), *EU R&D Scoreboard: The 2018 EU Industrial R&D Investment Scoreboard*, Office des publications de l'Union européenne, Luxembourg.
- Commission européenne (2019a), *Application du droit de la concurrence dans le secteur pharmaceutique (2009-2017): Collaboration entre les autorités européennes de la concurrence en vue de favoriser l'accès à des médicaments abordables et innovants*, Office des publications de l'Union européenne, Luxembourg.
- Commission européenne (2019b), *Report on the EU Customs Enforcement of Intellectual Property Rights: Results at the EU Border 2018*, Office des publications de l'Union européenne, Luxembourg.
- Commission européenne, Organisation panaméricaine de la santé et Organisation mondiale de la Santé (OMS) (2015), *Cuban Experience with Local Production of Medicines, Technology Transfer and Improving Access to Health*, OMS, Genève.
- Commission fédérale du commerce (FTC) des États-Unis (2009), *Emerging Health Care Issues: Follow-on Biologic Drug Competition*, FTC, Washington (D.C.).
- Commission fédérale du commerce (FTC) des États-Unis (2017), *Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in Fiscal Year 2015: A Report by the Bureau of Competition*, voir: <https://www.ftc.gov/reports/agreements-filed-federal-trade-commission-under-medicare-prescription-drug-improvement-9>.
- Commission fédérale du commerce (FTC) des États-Unis (2019), «Last Remaining Defendant Settles FTC Suit that Led to Landmark Supreme Court Ruling on Drug Company 'Reverse Payments'», communiqué de presse, 28 février 2019, voir: <https://www.ftc.gov/news-events/press-releases/2019/02/last-remaining-defendant-settles-ftc-suit-led-landmark-supreme>.
- Commission on Health Research for Development (1990), *Health Research: Essential Link to Equity in Development*, Oxford University Press, Oxford.
- Commission sur les droits de propriété intellectuelle, l'innovation et la santé publique (CIPIH) (2006), *Santé publique, innovation et droits de propriété intellectuelle: rapport de la Commission sur les droits de la propriété intellectuelle, l'innovation et la santé publique*, OMS, Genève.
- Conférence des Nations Unies sur le commerce et le développement (CNUCED) (2015a), *The model law on competition*, voir: <http://unctad.org/en/Pages/DITC/CompetitionLaw/The-Model-Law-on-Competition.aspx>.
- Conférence des Nations Unies sur le commerce et le développement (CNUCED) (2015b), *Le rôle de la concurrence dans le secteur pharmaceutique et ses avantages pour le consommateur*, TD/RBP/CONF.8/3.
- Congrès des États-Unis, Congressional Budget Office (USCBO - Bureau du budget du Congrès) (2006), *Research and Development in the Pharmaceutical Industry*, USCBO, Washington (D.C.).
- Congrès des États-Unis, Office of Technology Assessment (1993), *Pharmaceutical R&D: Costs, Risks and Rewards*, OTA-H-522, U.S. Government Printing Office, Washington (D.C.).
- Conley, J. M., Cook-Deegan, R. et Lázaro-Muñoz, G. (2014), «Myriad after Myriad: The proprietary data dilemma», *North Carolina Journal of Law and Technology* 15(4), pages 597 à 637.
- Conner-Simons, A. (2017), «Using artificial intelligence to improve early breast cancer detection», *MIT News*, version en ligne, 16 octobre 2017.
- Conseil des organisations internationales des sciences médicales (CIOMS) (2016), *Lignes directrices internationales d'éthique pour la recherche en matière de santé impliquant des participants humains*, CIOMS, Genève.
- Contreras, J. L. et Sherkow, J. S. (2017), «CRISPR, surrogate licensing, and scientific discovery», *Science* 355(6326), pages 698 à 700.
- Copenhagen Economics (2018), *Study on the Economic Impact of Supplementary Protection Certificates, Pharmaceutical Incentives and Rewards in Europe: Final Report*, Commission européenne, Bruxelles.
- Cornell University, INSEAD et OMPI (2019), *Global Innovation Index 2019: Creating Healthy Lives – The Future of Medical Innovation*, 12<sup>ème</sup> édition, Dutton, S., Lanvin, B. et Wunsch-Vincent, S. (éds), Cornell University, INSEAD et OMPI, Ithaca (New York), Fontainebleau et Genève.
- Cornish, W., Llewelyn, D. et Aplin, T. (2019), *Intellectual Property: Patents, Copyright, Trademarks & Allied Rights*, 4<sup>ème</sup> édition, Sweet and Maxwell, Londres.
- Correa, C. (2007), *Guidelines for the Examination of Pharmaceutical Patents: Developing a Public Health Perspective: A Working Paper*, CICDD, OMS et CNUCED, Genève.
- Correa, C. M. (2004), «Implementation of the WTO General Council Decision on Paragraph 6 of the DOHA Declaration on the TRIPS Agreement and Public Health», *Health Economics and Drugs Series*, n° 016, OMS, Genève.
- Correa, C. M. (2016), *Guidelines for Pharmaceutical Patent Examination: Examining Pharmaceutical Patents from a Public Health Perspective*, Programme des Nations Unies pour le développement (PNUD), New York.

- Costa Chaves, B., Gaspar Britto, W. et Fogaça Vieira, M. (2017), *MERCOSUR-EU Free Trade Agreement: Impact Analysis of TRIPS-Plus Measures Proposed by the EU on Public Purchases and Domestic Production of HIV and Hepatitis C Medicines in Brazil*, voir: <https://www.accesssbsa.org/media/2018/01/Mercosur-EU-Free-Trade-Agreement-HIV-Hepatitis-C.pdf>.
- Cotropia, C. A. (2008), «Compulsory Licensing Under TRIPS and the Supreme Court of the United States' Decision in eBay v. MercExchange», dans Takenaka, T. et Moufang, R. (éds), *Patent Law: A Handbook of Contemporary Research*, Edward Elgar Publishing Co, voir: <https://ssrn.com/abstract=1086142>.
- Cour des comptes des États-Unis (2017), *Drug Industry: Profits, Research and Development Spending, and Merger and Acquisition Deals*, GAO-18-40, voir: <https://www.gao.gov/assets/690/688472.pdf>.
- Creese, A. (2011), «Sales Taxes on Medicines», Projet OMS/HAI sur les prix et la disponibilité des médicaments, Examen des interventions et des politiques tarifaires en matière de produits pharmaceutiques, document de travail n° 5, OMS et HAI, Genève.
- Cross, R. W., Mire, C. E., Feldmann, H. et Geisbert, T. W. (2018), «Post-exposure treatments for Ebola and Marburg virus infections», *Nature Reviews Drug Discovery*, n° 17, pages 413 à 434.
- Crow, D. (2017), «Scientists shrug off failures in hunt for Alzheimer's treatments», *Financial Times*, version en ligne, 26 novembre 2017, voir: <https://www.ft.com/content/8d0db012-cda0-11e7-b781-794ce08b24dc>.
- Crowe, K. (2017), «Provinces spent \$43M on preemie drug experts say can be made for a fraction of the cost», *CBC News*, version en ligne, 7 avril 2017.
- Daniel, M. G., Pawlik, T. M., Fader, A. N., Esnaola, N. F. et Makary, M. A. (2016), «The Orphan Drug Act: Restoring the mission to rare diseases», *American Journal of Clinical Oncology* 39(2), pages 210 à 213.
- Danzon, P. M., Mulcahy, A. W. et Towse, A. K. (2015), «Pharmaceutical pricing in emerging markets: Effects of income, competition, and procurement», *Health Economics* 24(2), pages 238 à 252.
- Daulaire, N., Bang, A., Tomson, G., Kalyango, J. N. et Cars, O. (2015), «Universal access to effective antibiotics is essential for tackling antibiotic resistance», *Journal of Law, Medicine & Ethics* 43(3), pages 17 à 21.
- Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A. et Aggarwal, A. (2017), «Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: Retrospective cohort study of drug approvals 2009-13», *BMJ*, n° 359, page j4530.
- Deak, D., Outterson, K., Powers, J. H. et Kesselheim, A. S. (2016), «Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and Drug Administration-approved antibiotics, 2010–2015», *Annals of Internal Medicine* 165(5), pages 363 à 372.
- Deloitte (2018), *2018 Global Life Sciences Outlook: Innovating Life Sciences In the Fourth Industrial Revolution: Embrace, Build, Grow*, voir: <https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-ls-outlook-2018.pdf>.
- Deloitte (2019), *2019 Global Life Sciences Outlook: Focus and Transform: Accelerating Change in Life Sciences*, voir: <https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-ls-outlook-2019.pdf>.
- Deloitte Centre for Health Solutions (Centre de Deloitte pour les solutions de santé) (2018), *Unlocking R&D Productivity: Measuring the Return from Pharmaceutical Innovation 2018*, Deloitte, Londres.
- Diependaele, L., Cockbain, J. et Sterckx, S. (2017), «Raising the barriers to access to medicines in the developing world – the relentless push for data exclusivity», *Developing World Bioethics* 17(1), pages 11 à 21.
- DiMasi, J. A., Grabowski, H. G. et Hansen, R.W. (2016), «Innovation in the pharmaceutical industry: New estimates of R&D costs», *Journal of Health Economics*, n° 47, pages 20 à 33.
- DiMasi, J. A., Hansen, R. W. et Grabowski, H. G. (2003), «The price of innovation: New estimates of drug development costs», *Journal of Health Economics*, n° 22, pages 151 à 185.
- DiMasi, J. A., Hansen, R. W., Grabowski, H. G. et Lasagna, L. (1991), «Cost of innovation in the pharmaceutical industry», *Journal of Health Economics* 10(2), pages 107 à 142.
- Dong, J. et Mirza, Z. (2016), «Supporting the production of pharmaceuticals in Africa», *Bulletin de l'Organisation mondiale de la Santé* 94, pages 71 et 72.
- Dora, S., Khanna, D., Luo, Y., Poon, L. et Schweizer, C. (2017), *Medtech May Be Emerging Markets' Next New Thing*, Boston Consulting Group, voir: <https://www.bcg.com/en-ch/publications/2017/globalization-medical-devices-technology-medtech-may-be-emerging-markets-next-new-thing.aspx>.
- Dreyfuss, R. C., Nielsen, J. et Nicol, D. (2018), «Patenting nature - a comparative perspective», *Journal of Law and the Biosciences* 5(3), pages 550 à 589.
- Driehaus, J. (2012), «Patent Landscape in Molecular Diagnostics», dans Storz, U., Flasche, W., et Driehaus, J. (éds), *Intellectual Property Issues*, Springer, Berlin, Heidelberg, pages 73 à 106.
- Drugs for Neglected Diseases initiative (DNDi) (2014), *An Innovative Approach to R&D for Neglected Patients: Ten Years of Experience & Lessons Learned by DNDi*, DNDiGenève.
- Drugs for Neglected Diseases initiative (DNDi) (2019), *15 Years of Needs-Driven Innovation for Access: Key Lessons, Challenges, and Opportunities for the Future*, DNDi, Genève.
- Duggan, M. et Goyal, A. (2012), «Pharmaceutical Patents and Prices: A Preliminary Empirical Assessment Using Data from India», Policy Research Working Paper, n° 6063, Banque mondiale, Washington (D.C.).
- Ederington, J. et Rutta, M. (2016), «Non-Tariff Measures and the World Trading System», Policy Research Paper, Banque mondiale, voir: <http://documents.worldbank.org/curated/en/882991467989523068/pdf/WPS7661.pdf>.
- Elks, S. (2018), «Drug buyers' clubs aim to tackle HIV prevention 'crisis'», *Thomson Reuters Foundation News*, 3 décembre 2018, voir: <http://news.trust.org/item/20181130235707-qho8y/>.
- Espin, J., Rovira, J. et Olry de Labry, A. (2011), «External Reference Pricing», Projet OMS/HAI sur les prix et la disponibilité des médicaments, Examen des interventions et des politiques tarifaires en matière de produits pharmaceutiques, document de travail n° 1, OMS et HAI, Genève.
- EvaluatePharma [annuel], *World Preview*, Evaluate, Londres.

- EvaluatePharma, *World Preview 2013, Outlook to 2018: Returning to Growth*, voir: [https://info.evaluategroup.com/worldpreview2018\\_fp\\_lp.html](https://info.evaluategroup.com/worldpreview2018_fp_lp.html).
- EvaluatePharma (2018a), *Orphan Drug Report 2018*, 5ème édition, Evaluate, Londres.
- EvaluatePharma (2018b), *World Preview 2018, Outlook to 2024*, voir: <https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-world-preview-2018-outlook-2024#download>.
- Ewen, M., Joosse, H-J, Beran, D. et Laing, R. (2019), «Insulin prices, availability and affordability in 13 low-income and middle-income countries», *BMJ Global Health* 4(3), page e001410.
- Eyquem, J., Mansilla-Soto J., Giavridis, T., van der Stegen, S. J., Hamieh, M., Cunanan, K. M. et al. (2017), «Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection», *Nature* 543(7643), pages 113 à 117.
- Ferreira, R., David, F. et Nielsen, J. (2018), «Advancing biotechnology with CRISPR/Cas9: Recent applications and patent landscape», *Journal of Industrial Microbiology & Biotechnology* 45(7), pages 467 à 480.
- FIIM (2013), *Pharmaceutical R&D Projects to Discover Cures for Patients with Neglected Conditions: 2012 Status Report on Pharmaceutical R&D to Address Diseases that Disproportionately Affect People in Low- and Middle-Income Countries*, FIIM, Genève, voir: [https://www.ifpma.org/wp-content/uploads/2016/01/IFPMA\\_R\\_D\\_Status\\_Report\\_Neglected\\_Conditions.pdf](https://www.ifpma.org/wp-content/uploads/2016/01/IFPMA_R_D_Status_Report_Neglected_Conditions.pdf).
- FIIM (2017), *Doing Our Part: Innovating to Fight Neglected Tropical Diseases*, FIIM, Genève, voir: [https://www.ifpma.org/wp-content/uploads/2017/04/IFPMA\\_Innovating\\_to\\_Fight\\_NTDs\\_April2017\\_FINAL.pdf](https://www.ifpma.org/wp-content/uploads/2017/04/IFPMA_Innovating_to_Fight_NTDs_April2017_FINAL.pdf).
- Fink, C. (2011), «Intellectual Property Rights», dans Chauffour, J.-P. et Maur, J.-C. (éds), *Preferential Trade Agreement Policies for Development: A Handbook*, Banque mondiale, Washington (D.C.).
- Flynn, S. M., Hollis, A. et Palmedo, M. (2009), «An economic justification for open access to essential medicine patents in developing countries», *Journal of Law, Medicine and Ethics* 37(2), pages 184 à 208.
- Fojo, T., Mailankody, S. et Lo, A. (2014), «Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: The John Conley Lecture», *JAMA Otolaryngology – Head & Neck Surgery* 140(12), pages 1225 à 1236.
- Fonds international des Nations Unies pour l'enfance (UNICEF) (2019), *Human Papillomavirus Vaccine: Supply and Demand Update*, December 2019, voir: <https://www.unicef.org/supply/media/501/file/humanpapillomavirusHPVvaccinesupplyanddemandupdate.pdf>.
- Fonds mondial (2010), *Improving Value for Money in Global Fund-Supported Programs*, Fonds mondial, Genève.
- Fonds mondial (2018), *Guide to Global Fund Policies on Procurement and Supply Management of Health Products*, Fonds mondial, Genève.
- da Fonseca, E. M., Shadlen, K. et Bastos, F. I. (2019), «Brazil's fight against hepatitis C: Universalism, local production, and patents», *New England Journal of Medicine*, n° 380, pages 605 à 607.
- Fontein, C., Akker, I. et Sauter, W. (2018), «Reconciling competition and IP law: the case of patented pharmaceuticals and dominance abuse», document de travail de l'ACM, voir: <http://eplaw.org/wp-content/uploads/2018/03/ACM-working-paper-dominance-and-patented-pharmaceuticals.pdf>.
- «Forging paths to improve diabetes care in low-income settings» (2017), éditorial, *The Lancet Diabetes & Endocrinology* 5(8), page 565.
- Friede, M., Palkonyay, L., Alfonso, C., Pervikov, Y. et al. (2011), «WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer», *Vaccine*, n° 29, Supplément 1:A2-7.
- Frost, L. J. et Reich, M. R. (2010), *Access: How Do Good Health Technologies Get to Poor People in Poor Countries?*, Harvard Center for Population and Development Studies, Cambridge (Massachusetts).
- Fry, A. (2012), «Insulin Delivery Device Technology 2012: Where Are We After 90 Years?», *Journal of Diabetes Science and Technology* 6(4), pages 947 à 953.
- Gaessler, F. et Wagner, S. (2018), «Patents, Data Exclusivity and the Development of New Drugs», avant-projet préparé pour la 11<sup>ème</sup> Annual Searle Centre/USPTO Conference on Innovation Economics, travaux en cours, 3 juin 2018.
- Gainey, L. (2018), «How the EPO treats personalised healthcare patents», *Life Sciences Intellectual Property Review*, version en ligne, 12 octobre 2018.
- Gammie, T., Lu, C. Y., et Babar Z. U. (2015), «Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries», *PLoS ONE*, 9 octobre 2015, n° 10, page e0140002.
- Gapper, J. (2019), «Keytruda shows the high price of curing cancer», *Financial Times*, version en ligne, 13 février 2019, <https://www.ft.com/content/c1dacc6-2ec2-11e9-ba00-0251022932c8>.
- Garner, S., Rintoul, A. et Hill, S. R. (2018), «Value-based pricing: L'enfant terrible?», *Pharmacoeconomics* 36(1), pages 5 et 6.
- Garrido, M. V., Kristensen, F. B., Nielsen, C. P. et Busse, R. (2008), *Health Technology Assessment and Health Policy-Making in Europe: Current Status, Challenges and Potential*, Observatory Studies Series, n° 14, OMS, Genève, pour l'Observatoire européen des systèmes et des politiques de santé.
- Gaudillière, J. (2008), «How pharmaceuticals became patentable: the production and appropriation of drugs in the twentieth century», *History and Technology*, n° 24, pages 99–106.
- Gavi (2018), *Advance Market Commitment for Pneumococcal Vaccines, Annual Report 1 January - 31 December 2018*, voir: <https://www.gavi.org/investing/innovative-financing/pneumococcal-amc/>.
- Gavi (2019), *How We Work Together: Quick start guide for new members of the Vaccine Alliance*, voir: <https://www.gavi.org/library/publications/gavi/how-we-work-together/>.
- GE Healthcare (2011), «Market-relevant design: Making ECGs available across India», *The Pulse on Health, Science & Tech*, 30 septembre 2011.

- Geis, J. R., Brady, A., Wu, C. C., Spencer, J., Kohli, M., Ranschaert, E. *et al* (2019), *Ethics of AI in Radiology: European and North American Multisociety Statement*.
- Generics and Biosimilars Initiative (GaBI) (2018a), «Guidelines for biosimilars around the world», *GaBI Online*, 13 avril 2018.
- Generics and Biosimilars Initiative (GaBI) (2018b), «Similar biologics approved and marketed in India», *GaBI Online*, 15 février 2018.
- Giannuzzi, V., Conte, R., Landi, A., Ottomano, S. A., Bonifazi, D., Baiardi, P. *et al.* (2017), «Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: An increased common effort is to be foreseen», *Orphanet Journal of Rare Diseases* 12(1), page 64.
- Gilbert, R. (2019), «Competition, mergers and R&D diversity», *Review of Industrial Organization* 54(3), pages 465 à 484.
- Gillmore Valenzuela, I. et Santos Ossa Rogat, J., «Protección y Exclusividad de Datos de Prueba de Productos Farmacéuticos en Chile», voir: <https://revistas.uchile.cl/index.php/RDE/articulo/download/47370/49414/>.
- GlaxoSmithKline (2019a), «GSK announces availability of Authorized Generic Albuterol Sulfate Inhaler for treatment or prevention of bronchospasm», communiqué de presse, voir: <https://us.gsk.com/en-us/products/ventolin-authorized-generic-statement/>.
- GlaxoSmithKline (2019b), «GSK grants exclusive technology license for clinical-stage Ebola vaccines to Sabin Vaccine Institute», communiqué de presse, voir: <https://www.gsk.com/en-gb/media/press-releases/gsk-grants-exclusive-technology-license-for-clinical-stage-ebola-vaccines-to-sabin-vaccine-institute/>.
- Goldacre, B., DeVito, N. J., Heneghan, C., Irving, F., Bacon, S., Fleming, J. *et al.* (2018), «Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and web resource», *BMJ*, n° 362, page k3218.
- Goldman, D. P., Lakdawalla, D. N., Malkin, J. D., Romley, J. et T. Philipson (2011), «The benefits from giving makers of conventional 'small molecule' drugs longer exclusivity over clinical trial data», *Health Affairs* 30(1), pages 84 à 90.
- Gómez-Dantés, O., Wirtz, V. J., Reich, M. R., Terrazas, P. *et al.* (2012), «Une nouvelle entité pour la négociation des prix publics d'achat des médicaments brevetés au Mexique», *Bulletin de l'Organisation mondiale de la Santé* 90, pages 788 à 792, voir: <https://www.who.int/bulletin/volumes/90/10/12-106633-ab/fr/>.
- Gordon, R. J. (2018), «Why Has Economic Growth Slowed When Innovation Appears to be Accelerating?», document de travail n° 24554, National Bureau of Economic Research (NBER), Cambridge (Massachusetts).
- Gornall, J., Hoey, A. et Ozieranski, P. (2016), «A pill too hard to swallow: how the NHS is limiting access to high priced drugs», *BMJ*, n° 354, page i4117.
- Gotham, D., Barber, M. J. et Hill, A. (2018), «Production costs and potential prices for biosimilars of human insulin and insulin analogues», *BMJ Global Health* 3(5), page e000850.
- Grabowski, H. G. et Kyle, M. (2007), «Generic competition and market exclusivity periods in pharmaceuticals», *Managerial and Decision Economics* 28(4-5), pages 491 à 502.
- Greene, J. A. (2010), «When did medicines become essential?», *Bulletin de l'Organisation mondiale de la Santé* 88(7), page 483.
- Griliches, Z. (1994), «Productivity, R&D, and the data constraint», *American Economic Review* 84(1), pages 1 à 23.
- Grohmann, G., Francis, D. P., Sokhey, J. et Robertson, J. (2016), «Challenges and successes for the grantees and the Technical Advisory Group of WHO's influenza vaccine technology transfer initiative», *Vaccine* 34(45), pages 5420 à 5424.
- Gross, N. J. (2007), «Albuterol inhalers», *New England Journal of Medicine* 356(26), réponse de l'auteur, page 2749.
- Grössmann N, Del Paggio JC, Wolf S, *et al.* (2017), «Five years of EMA-approved systemic cancer therapies for solid tumours—a comparison of two thresholds for meaningful clinical benefit», *European Journal of Cancer*, n° 82, pages 66 à 71.
- Groupe de haut niveau sur l'accès aux technologies de la santé (Groupe de haut niveau des Nations Unies) (2016), *Rapport du Groupe de haut niveau du Secrétaire général des Nations Unies sur l'accès aux médicaments: Promouvoir l'innovation et l'accès aux technologies de la santé*, Groupe de haut niveau des Nations Unies, New York.
- Guebert, J. M. et Bubela, T. (2014), «Implementing socially responsible licensing for global health: Beyond neglected diseases», *Science Translational Medicine* 6(260), pages 260cm11.
- Gupta, R., Shah, N. D. et Ross J. S. (2016), «The Rising Price of Naloxone—Risks to Efforts to Stem Overdose Deaths», *The New England Journal of Medicine*, n° 375, pages 2213 à 2215, voir: <http://www.nejm.org/doi/full/10.1056/NEJMp1609578#t=article>.
- Gupta, R., Shah, N. D. et Ross J. S. (2019), «Generic Drugs in the United States: Policies to Address Pricing and Competition», *Clinical Pharmacology & Therapeutics*, n° 105, pages 329 à 337.
- Harrer, S., Shah, P., Antony, B. et Hu, J. (2019), «Artificial Intelligence for clinical trial design», *Trends in Pharmacological Sciences* 40(8), pages 577 à 591.
- Hawkins, L. (2011), «Competition Policy», Projet OMS/HAI sur les prix et la disponibilité des médicaments, Examen des interventions et des politiques tarifaires en matière de produits pharmaceutiques, document de travail n° 4, OMS et HAI, Genève.
- Henao-Restrepo, A. M., Camacho, A., Longini, I. M., Watson, C. H., Edmunds, J., Egger, M. *et al.* (2017), «Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)», *The Lancet* 389(10068), pages 505 à 518.
- Herbert, M. (2018), «Enabling Innovation: SME-driven Pharmaceutical and Life Science Market Growth», UK-CPI, voir: <https://www.uk-cpi.com/blog/enabling-innovation-sme-driven-pharmaceutical-and-life-science-market-growth>.
- Herper, M. (2012), «The truly staggering cost of inventing new drugs», *Forbes*, version en ligne, 10 février 2012.
- Hill, A., Simmons, B., Gotham, D. et Fortunak, J. (2016), «Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C», *Journal of Virus Eradication* 2(1), pages 28 à 31.
- Hill, A. M., Barber, M. J. et Gotham, D. (2018), «Estimated costs of production and potential prices for the WHO Essential Medicines List», *BMJ Global Health*, n° 3, page e000571.
- HM Revenue & Customs (2016), *Policy paper: Vaccine research relief: expiry in 2017*, voir: <https://www.gov.uk/government/publications/vaccine-research-relief-expiry-in-2017/vaccine-research-relief-expiry-in-2017>.

- 't Hoen, E., Berger, J., Calmy, A. et Moon, S. (2011), «Driving a decade of change: HIV/AIDS, patents and access to medicines for all», *Journal of the International AIDS Society*, n° 14, page 15.
- 't Hoen, E. F. M. (2009), *The Global Politics of Pharmaceutical Monopoly Power: Drug Patents, Access, Innovation and the Application of the WTO Doha Declaration on TRIPS and Public Health*, AMB Publishers, Diemen (Pays-Bas).
- 't Hoen, E. F. M. (2014), *Access to Cancer Treatment: A Study of Medicine Pricing Issues with Recommendations for Improving Access to Cancer Medication: A Report Prepared for Oxfam*.
- 't Hoen, E. F. M., Boulet, P., Baker, B. K. (2017), «Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation», *Journal of Pharmaceutical Policy and Practice*, n° 10, page 19.
- 't Hoen, E. F. M., Veraldi, J., Toebes, B. et Hogerzeil, H. V. (2018), «Achat de médicaments et recours aux flexibilités de l'Accord sur les aspects des droits de propriété intellectuelle qui touchent au commerce, 2001-2016», *Bulletin de l'Organisation mondiale de la Santé*, n° 96, pages 185 à 193.
- Hogarth, S., Hopkins, M. M. et Rodriguez, V. (2012), «A molecular monopoly? HPV testing, the Pap smear and the molecularisation of cervical cancer screening in the USA», *Sociology of Health & Illness* 34(2), pages 234 à 250.
- Hogerzeil, H. V. et Mirza, Z. (2011), *The World Medicines Situation 2011: Access to Essential Medicines as Part of the Right to Health*, OMS, Genève.
- Hogerzeil, H. V., Samson, M., Casanovas, J. V. et Rahmani-Ocora, L. (2006), «Is access to essential medicines as part of the fulfilment of the right to health enforceable through the courts?», *The Lancet* 368(9532), pages 305 à 311.
- Holloway, K. et van Dijk, L. (2011), *The World Medicines Situation 2011: Rational Use of Medicines*, OMS, Genève.
- Holman, C. M. (2014), «Mayo, Myriad, and the future of innovation in molecular diagnostics and personalized medicine», *North Carolina Journal of Law & Technology* 15(4), pages 639 à 678.
- Hopkins, M. M. et Hogarth, S. (2012), «Biomarker patents for diagnostics: problem or solution?», *Nature Biotechnology* 30(6), pages 498 à 500.
- Hughes, D.A., Poletti-Hughes, J. (2016) «Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study», *PLoS ONE* 11(10), page e0164681.
- Husereau, D. et Cameron, C. (2011), «Value-Based Pricing of Pharmaceuticals in Canada: Opportunities to Expand the Role of Health Technology», *CHSRF Series of Reports on Cost Drivers and Health System Efficiency*, document n° 5, Fondation canadienne de la recherche sur les services de santé (FCRSS), Ottawa.
- Immelt, J.R., Govindarajan, V. et Trimble, C. (2009), «How GE is disrupting itself», *Harvard Business Review*, version en ligne, octobre 2009.
- Interagency Coordination Group on Antimicrobial Resistance (IACG) (2018), «Antimicrobial resistance: Invest in innovation and research, and boost R&D and access», document de synthèse de l'IACG, juin 2018, voir: [https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG\\_AMR\\_Invest\\_innovation\\_research\\_boost\\_RD\\_and\\_access\\_110618.pdf?ua=1](https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_AMR_Invest_innovation_research_boost_RD_and_access_110618.pdf?ua=1).
- Interagency Coordination Group on Antimicrobial Resistance (IACG) (2019), *Pas le temps d'attendre: Assurer l'avenir contre les infections résistantes aux médicaments: Rapport au Secrétaire général des Nations Unies*.
- International Diabetes Federation (2016), *Access to Medicines and Supplies for People with Diabetes: A Global Survey on Patients' and Health Professionals' Perspective*, voir: <https://www.idf.org/component/attachments/?task=download&id=1965>.
- Ivanovska, V., Rademaker, C. M. A., van Dijk, L., et Mantel-Teeuwisse, A. K. (2014), «Pediatric drug formulations: A review of challenges and progress», *Pediatrics* 134(2), pages 361 à 372.
- Iyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., de Joncheere, K. et al. (2016), «Prices, costs, and affordability of new medicines for Hepatitis C in 30 countries: An economic analysis», *PLOS Medicine* 13(5), page e1002032.
- Jamison, D. T., Summers, L. H., Alleyne, G., Arrow, K. J., Berkley, S., Binagwaho, A. et al. (2013), «Global health 2035: A world converging within a generation», *The Lancet*, n° 382, pages 1898 à 1955.
- Jaspers, L., Colpani, V., Chaker, L., van der Lee, S. J., Muka, T., Imo, D. et al. (2015), «The global impact of non-communicable diseases on households and impoverishment: A systematic review», *European Journal of Epidemiology* 30(3), pages 163 à 188.
- Jayasundara, K., Hollis, A., Krahn, M., Mamdani, M., Hoch, J. S. et Grootendorst, P. (2019), «Estimating the clinical cost of drug development for orphan versus non-orphan drugs», *Orphanet Journal of Rare Diseases*, n° 14, page 12.
- Jena, A. B., Ho, O., Goldman, D. P. et Karaca-Mandic, P. (2015), «The impact of the US Food and Drug Administration chlorofluorocarbon ban on out-of-pocket costs and use of Albuterol inhalers among individuals with asthma», *JAMA Internal Medicine* 175(7), pages 1171 à 1179.
- Jenner, A., Bhagwandin, N. et Kowalski, S. (2017), *Antimicrobial Resistance (AMR) and Multidrug Resistance (MDR): Overview of Current Approaches, Consortia and Intellectual Property Issues*, OMPI, Genève.
- Jewell, C. et Balakrishnan, V. S. (2017), «The battle to own the CRISPR-Cas9 gene-editing tool», *Magazine de l'OMPI*, n° 2, version en ligne, avril 2017.
- de Jongh, T., Radauer, A., Bostyn, S. et Poort, J. (2018), *Effects of Supplementary Protection Mechanisms for Pharmaceutical Products: Final Report, May 2018*, Technopolis Group, Amsterdam.
- Jürgens, B. et Clarke, N. S. (2019), «Evolution of CAR T-cell immunotherapy in terms of patenting activity», *Nature Biotechnology*, n° 37, pages 370 à 375.
- Kahn, J. et Lauerman, J. (2018), «Google taking over health records raises patient privacy fears», *Bloomberg*, version en ligne, 21 novembre 2018.
- Kaltenboeck, A. et Bach, P. B. (2018), «Value-based pricing for drugs: Theme and variations», *JAMA* 319(21), pages 2165 et 2166.
- Kampf, R. (2015), «Special Compulsory Licences for Export of Medicines: Key Features of WTO Members' Implementing Legislation», document de travail ERSD-2015-07, OMC, Genève.
- Kaplan, W. A. et Beall, R. F. (2016), «The global intellectual property ecosystem for insulin and its public health implications: An observational study», *Journal of Pharmaceutical Policy and Practice*, n° 10, page 3.



- Kartikeyan, S., Bharmal, R. N., Tiwari, R. P. et Bisen, P. S. (2007), *HIV and AIDS: Basic elements and priorities*, Springer, 2007, Dordrecht.
- Kesselheim, A. S. (2010) «Using market-exclusivity incentives to promote pharmaceutical innovation», *New England Journal of Medicine*, n° 363, pages 1855 à 1862.
- Kesselheim, A. S., Misono, A. S., Shrank, W. H., Greene, J. A., Doherty, M., Avorn, J. et al. (2013), «Variations in pill appearance of antiepileptic drugs and the risk of nonadherence», *JAMA Internal Medicine* 173(3), pages 202 à 208.
- Kesselheim, A. S. et Solomon, D. H. (2010), «Incentives for drug development - the curious case of colchicine», *New England Journal of Medicine*, n° 362, pages 2045 à 2047.
- Khor, M. (2007), «Patents, Compulsory Licences and Access to Medicines: Some Recent Experiences», TWN Intellectual Property Series, n° 10, Third World Network (TWN), Penang (Malaisie).
- Kim, C. et Prasad, V. (2015), «Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of US Food and Drug Administration approvals», *JAMA Internal Medicine*, n° 359, pages 1992 à 1994.
- King, D. R. et Kanavos, P. (2002), «Encouraging the use of generic medicines: Implications for transition economies», *Croatian Medical Journal* 43(4), pages 462 à 469.
- Kittittrakul, C. (2018a), présentation faite au Academic Forum on Lessons Learned of Drug Patents' Opposition and Withdrawal, tenu le 18 mai 2018 à la Faculté des sciences pharmaceutiques, Université de Chulalongkorn, Thaïlande.
- Kittittrakul, C. (2018b), présentation faite à la Civil Society Organizations' Meeting on Hepatitis C: Emerging Evidences and Scaling-up Response, 6 et 7 juin 2018, Bangkok.
- Kmietowicz, Z. (2015a), «Campaigners demand right to generic version of breast cancer drug», *BMJ*, n° 351, page h5279.
- Kmietowicz, Z. (2015b), «China rejects patent on hepatitis C drug sofosbuvir», *BMJ*, n° 350, page h3429.
- Kneller, R. (2010), «The importance of new companies for drug discovery: Origins of a decade of new drugs», *Nature Reviews Drug Discovery*, n° 9, pages 867 à 882.
- Kohli, M. et Geis, R. (2018), «Ethics, Artificial Intelligence, and Radiology», *Journal of the American College of Radiology* 15(9), pages 1317 à 1319.
- Kolata, G. (1991), «Patients Going Underground to Buy Experimental Drugs», *New York Times*, section A, page 1, voir: <https://www.nytimes.com/1991/11/04/us/patients-going-underground-to-buy-experimental-drugs.html?searchResultPosition=22>.
- de Kraker, M.E.A., Stewardson, A.J. et Harbarth, S. (2016), «Will 10 million people die a year due to antimicrobial resistance by 2050?», *PLoS Medicine* 13(11), page e1002184.
- Krasovec, K. et Connor, C. (1998), *Using Tax Relief to Support Public Health Goals*, Partners for Health Reformplus.
- Krattiger, A. (2007a), «Freedom to Operate, Public Sector Research, and Product-Development Partnerships, Strategies, and Risk-Management Options», dans Krattiger, A. et al. (éds), *Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices*, Centre for the Management of Intellectual Property in Health Research and Development (MIHR) et Public Intellectual Property Resource for Agriculture (PIPRA), Oxford et Davis (Californie), pages 1317 à 1327.
- Krattiger, A. (2007b), «The Use of Nonassertion Covenants: A Tool to Facilitate Humanitarian Licensing, Manage Liability, and Foster Global Access», dans Krattiger, A. et al. (éds), *Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices*, Centre for the Management of Intellectual Property in Health Research and Development (MIHR) et Public Intellectual Property Resource for Agriculture (PIPRA), Oxford et Davis (Californie), pages 739 à 745.
- Krattiger, A., Bombelles, T., Bartels, H. G., Mirza, Z., Beyer, P., Taubman, A. et al. (2015), «Promoting Medical Innovation and Access Together: Trilateral Cooperation between WHO, WIPO and WTO», *Global Challenges Brief on Trilateral Cooperation*, OMPI, Genève.
- Kulkarni, P.S., Socquet, M., Jadhav, S.S., Kapre, S.V., LaForce, F.M. et Poonawalla, C.S. (2015), «Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective from the Serum Institute of India», *Clinical Infectious Diseases*, n° 61, pages S483 à S488.
- Kwon, D. (2019), «A brief guide to the current CRISPR landscape», *The Scientist*, version en ligne, 15 juillet 2019.
- Kyle, M. et Qian, Y. (2014), «Intellectual Property Rights and Access to Innovation: Evidence from TRIPS», document de travail n° 20799, National Bureau of Economic Research (NBER), Cambridge (Massachusetts).
- LaMattina, J. L. (2011), «The impact of mergers on pharmaceutical R&D», *Nature Reviews, Drug Discovery*, n° 10, pages 559 et 560.
- LaMattina, J. L. (2015), «FDA approvals 1996 vs. 2014: The two most prolific years, but stark differences», *Forbes*, version en ligne, 7 janvier 2015.
- Lander, E., Baylis, F., Zhang, F., Charpentier, E., Berg, P. et al. (2019), «Adopt a moratorium on heritable genome editing», *Nature*, version en ligne, 13 mars 2019.
- Langreth, R. (2019), «Alzheimer's Drug Failure Leaves Scientists Seeking New Direction», *Bloomberg*, version en ligne, 22 mars 2019, voir: <https://www.bloomberg.com/news/articles/2019-03-22/alzheimer-s-drug-fails-and-scientists-ask-is-it-time-to-move-on>.
- Lanjou, J. O. (2005), «Patents, Price Control, and Access to New Drugs: How Policy Affects Global Market Entry», document de travail n° 11321, National Bureau of Economic Research (NBER), Cambridge (Massachusetts).
- Laustsen, A. H., Johansen, K. H., Engmark, M. et Andersen, M. R. (2017), «Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?» *PLoS Neglected Tropical Diseases* 11(2), page e0005361.
- Laxminarayan, R., Matsuoka, P., Pant, S., Brower, C., Røttingen, J.-A., Klugman, K. et al. (2016), «Access to effective antimicrobials: A worldwide challenge», *The Lancet* 387(10014), pages 168 à 175.
- Lesser, N. et Hefner, M. (2017), «R&D partnerships – Partnering for progress: How collaborations are fuelling biomedical advances», *Drug Development*, version en ligne, novembre-décembre 2017.
- Leucht, S., Helfer, B., Gartlehner, G. et Davis, J. M. (2015), «How effective are common medications: A perspective based on meta-analyses of major drugs», *BMC Medicine*, n° 13, page 253.

- Levin, R. C., Klevorick, A. K., Nelson, R. R. et Winter, S. G. (1987), «Appropriating the Returns from Industrial Research and Development», *Brookings Papers on Economic Activity*, n° 3, pages 783 à 831.
- Lexchin, J. (2012), «International comparison of assessments of pharmaceutical innovation», *Health Policy* 105(2–3), pages 221 à 225.
- Lichtenberg, F. (2012), «Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-Income Countries, 2000–2009», document de travail n° 18235, National Bureau of Economic Research (NBER), Cambridge (Massachusetts).
- Lloyd, M. (2013), «Evergreening by whom? A review of secondary patents for omeprazole», *Pharmaceutical Patent Analyst* 2(6), voir: <http://www.future-science.com/doi/abs/10.4155/ppa.13.57>.
- Lock, H. (2019), «Fight the fakes: how to beat the \$200bn medicine counterfeiters», *The Guardian*, 5 juin 2019.
- Long, G. (2017), *The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development*, Analysis Group, Boston (Massachusetts).
- Love, J. (2003), «Evidence Regarding Research and Development Investments in Innovative and Non-Innovative Medicines», Consumer Project on Technology, Washington (D.C.).
- Lunze, A. (2019), «No compulsory licence for Sanofi's Praluent in Germany», voir: <https://united-kingdom.taylorwessing.com/synapse/ti-sanofi-licence.html>.
- Luo, J. et Kesselheim, A. S. (2015) «Evolution of insulin patents and market exclusivities in the USA», *The Lancet Diabetes & Endocrinology* 3(11), pages 835 à 837.
- Mackey, T. K. et Liang, B. A. (2012), «Patent and exclusivity status of essential medicines for non-communicable disease», *PLoS ONE* 7(11), page e51022.
- Madian, A. G., Wheeler, H. E., Jones, R. B. et Dolan, M. E. (2012), «Relating human genetic variation to variation in drug responses», *Trends in Genetics* 28(10), pages 487 à 495.
- Magrini, N., Robertson, J., Forte, G., Cappello, B., Moja, L. P., de Joncheere, K. et al. (2015), «Tough decisions on essential medicines in 2015», *Bulletin de l'Organisation mondiale de la Santé* 93, pages 283 et 284.
- Maistat, L., Kravchenko, N. et Reddy, A. (2017), «Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries», *Hepatology, Medicine and Policy*, n° 2, page 9. DOI: 10.1186/s41124-017-0026-z.
- Makin, S. (2018), «The amyloid hypothesis on trial», *Nature*, n° 559, pages S4 à S7.
- Malerba, F. et Orsenigo, L. (2015), «The evolution of the pharmaceutical industry», *Business History* 57(5), pages 664 à 687.
- Management Sciences for Health (MSH) (2012), *MDS-3: Managing Access to Medicines and Health Technologies*, MSH, Arlington (Virginia).
- Mandel, G. N. (2006), «The generic biologics debate: Industry's unintended admission that biotech patents fail enablement», *Virginia Journal of Law & Technology* 11(8).
- Maniadakis, N., Holtorf, A.-P., Otávio Corrêa, J. O., Gialama, F. et Wijaya, K. (2018), *Applied Health Economics and Health Policy* 16(5), pages 591 à 607.
- Mansfield, E. (1986), «Patents and innovation: An empirical study», *Management Science* 32(2), pages 173 à 181.
- Marks, L. V. (2015), *The Lock and Key of Medicine: Monoclonal Antibodies and the Transformation of Healthcare*, Yale University Press, New Haven.
- Marshall, A. D., Cunningham, E. B., Nielsen, S., Aghemo, A., et al. (2018), «Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe», *The Lancet Gastroenterology & Hepatology* 3(2), pages 125 à 133.
- Martin-Laffon, J., Kuntz, M. et Ricroch, A. E. (2019), «Worldwide CRISPR patent landscape shows strong geographical biases», *Nature Biotechnology*, n° 37, pages 613 à 620.
- Martinez, C. (2010), «Insight into Different Types of Patent Families», documents de travail de l'OCDE sur la science, la technologie et l'industrie n° 2010/02, Éditions OCDE, Paris.
- Masini, T., Hauser, J., Kuwana, R., Nhat Linh, N. et Jaramillo, E. (2018), «Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid?» *European Respiratory Journal* 51(3), page 1702480.
- Masum, H. et Harris, R. (2011), *Open Source for Neglected Disease: Magic Bullet or Mirage?*, Results for Development Institute, Washington (D.C.).
- Matthijs, G. et van Ommen, G.-J. B. (2009), «Gene Patents: From Discovery to Invention. A Geneticist's View», dans Van Overwalle, G. (éd.), *Gene Patents and Collaborative Licensing Models: Patent Pools, Clearinghouses, Open Source Models and Liability Regimes*, Cambridge University Press, Cambridge (Royaume-Uni).
- Maurer, S. (2007), «Open source drug discovery: Finding a niche (or maybe several)», *UMKC Law Review* 76(2), pages 405 à 435.
- McConaghie, A. (2019), «Orkambi row: government now considering Crown Use licensing», *PMLive*, 20 juin 2019, voir: [http://www.pmlive.com/pharma\\_news/orkambi\\_row\\_government\\_says\\_now\\_considering\\_crown\\_licensing\\_1290525](http://www.pmlive.com/pharma_news/orkambi_row_government_says_now_considering_crown_licensing_1290525).
- McDonald, S. A., Mohamed, R., Dahlui, M., Nanning, H., et al. (2014), «Bridging the data gaps in the epidemiology of hepatitis C virus infection in Malaysia using multi-parameter evidence synthesis», *BMC Infectious Diseases* 14(564), DOI: 10.1186/s12879-014-0564-6.
- Médecins Sans Frontières (MSF) (2016), «MSF launches challenge to Pfizer's patent on the pneumonia vaccine in India to increase access to more affordable versions», voir: <https://www.msf.org/access-msf-launches-challenge-pfizers-patent-pneumonia-vaccine-india-increase-access-more>.
- Médecins Sans Frontières (MSF) (2018), «A fair shot for affordable pneumonia vaccine: Why overcoming patent barriers to PCV13 is vital for saving children's lives?», *Rinsho Hyoka=Clinical Evaluation* 46(2): pages W45–W48, voir: [http://cont.o.oo7.jp/46\\_2/w45-w48.pdf](http://cont.o.oo7.jp/46_2/w45-w48.pdf).
- Megget, K. (2018), «Novartis exit from antibiotics a setback for race against resistance», *Chemistry World*, voir: <https://www.chemistryworld.com/news/novartis-exit-from-antibiotics-a-setback-for-race-against-resistance/3009316.article>.
- Merges, R. P. et Mattioli, M. (2017), «Measuring the costs and benefits of patent pools», *Ohio State Law Journal* 78(2), pages 281 à 347.
- Miller, J. (2018), «Novartis's pricing might be tested with costly eye therapy», Reuters, version en ligne, 23 novembre 2018, voir: <https://www.reuters.com/article/us-novartis-luxturna/novartiss-pricing-might-be-tested-with-costly-eye-therapy-idUSKCN1NS0FM>.

- Miller, K. L. et Lanthier, M. (2018), «Investigating the landscape of US orphan product approvals», *Orphanet Journal of Rare Diseases*, n° 13, page 183.
- Miller, S. et Hicks G. N. (2015), «Investor-State Dispute Settlement: A Reality Check», Center for Strategic and International Studies, voir: [https://csis-prod.s3.amazonaws.com/s3fs-public/legacy\\_files/files/publication/150116\\_Miller\\_InvestorStateDispute\\_Web.pdf](https://csis-prod.s3.amazonaws.com/s3fs-public/legacy_files/files/publication/150116_Miller_InvestorStateDispute_Web.pdf).
- Ministère de la santé de la Fédération de Russie et Organisation mondiale de la Santé (OMS) (2017), *Moscow Declaration to End TB*, première Conférence ministérielle mondiale: Ending TB in the Sustainable Development Era: A Multisectoral Response, 16–17 novembre 2017, Moscou (Fédération de Russie).
- Mirza, Z. (2008), «Thirty years of essential medicines in primary health care», *Eastern Mediterranean Health Journal*, n° 14 (suppl.), pages S74 à S81.
- Mohara, A., Yamabhai, I., Chaisiri, K., Tantivess, S. et Teerawattananon, Y. (2012), «Impact of the introduction of government use licenses on the drug expenditure on seven medicines in Thailand», *Value in Health* 15(1) (suppl.), pages S95 à S99.
- Mok, K. (2018), «IBM combines AI and blockchain to identify counterfeits», *The New Stack*, 22 juin 2018.
- Mongan, A.-M. (2018), «Tech Giants Tackle Health Care: An Opportunity or Threat for the Pharmaceutical Industry», *Clinical Trials Arena*, version en ligne, 7 août 2018, voir: <https://www.clinicaltrialsarena.com/comment/tech-giants-tackle-health-care-opportunity-threat-pharmaceutical-industry/>.
- Moon, S. (2011), *Pharmaceutical Production and Related Technology Transfer*, OMS, Genève.
- Moon, S. et Erickson, E. (2019), «Universal medicine access through lump-sum remuneration – Australia's approach to Hepatitis C», *New England Journal of Medicine*, n° 380, pages 607 à 610.
- Moran, M., Ropars, A.-L., Guzman, J., Diaz, J. et Garrison, C. (2005), *The New Landscape of Neglected Disease Drug Development*, The Wellcome Trust, Londres.
- Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C. et Greyson, D. (2011), «The cost of drug development: A systematic review», *Health Policy* 100(1), pages 4 à 17.
- Mowery, D. C. et Sampat, B. N. (2001a), «Patenting and licensing university inventions: lessons from the history of the research corporation», *Industrial and Corporate Change* 10(2), pages 317 à 355.
- Mowery, D. C. et Sampat, B. N. (2001b), «University patents and patent policy debates in the USA, 1925-1980», *Industrial and Corporate Change* 10(3), pages 781 à 814.
- MRC Laboratory of Molecular Biology (1984), «1984 Physiology or Medicine Prize – César Milstein & Georges Köhler», voir: <http://www2.mrc-lmb.cam.ac.uk/achievements/lmb-nobel-prizes/1984-cesar-milstein-georges-kohler/>.
- Mulcahy, A. W., Predmore, Z. et Mattke, S. (2014), *The Cost Savings Potential of Biosimilar Drugs in the United States*, RAND Corporation, Santa Monica (Californie).
- Mullard, A. (2019), «Anti-amyloid failures stack up as Alzheimer antibody flops», *Nature Reviews Drug Discovery*, version en ligne, 5 avril 2019.
- Mullin, E. (2017), «CRISPR in 2018: Coming to a human near you», *MIT Technology Review*, version en ligne, 18 décembre 2017.
- Murray, C. J. L. et Lopez, A. D. (éds) (1996), *The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020*, Harvard School of Public Health, Boston (Massachusetts).
- National Institutes of Health (NIH) (2001), *Glossary of Terms for Human Subjects Protection and Inclusion Issues*, NIH, Washington (D.C.).
- National Research Council (2003), *Patents in the Knowledge-Based Economy*, The National Academies Press, Washington (D.C.), voir: <https://doi.org/10.17226/10770>.
- National Research Council (2011), *Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease*, The National Academies Press, Washington (D.C.), voir: <https://doi.org/10.17226/13284>.
- NCD Alliance (2011), «Access to Essential Medicines and Technologies for NCDs», document d'information, NCD Alliance, Genève.
- Newsome, C. (2017), «Basaglar», *Clinical Diabetes* 35(3), page 181.
- Nguyen, T-Y, Veras, J et Shahzad, M. (2018), «Recent Experiences in Policy Implementation of Socially Responsible Licensing in Select Universities Across Europe and North America: Identifying Key Provisions to Promote Global Access to Health Technologies», *Les Nouvelles: The Journal of the Licensing Executives Society International* LIII(3).
- Niëns, L., Cameron, A., Van de Poel, E., Ewen, M., Brouwer, W. B. et Laing, R. (2010), «Quantifying the impoverishing effects of purchasing medicines: A cross-country comparison of the affordability of medicines in the developing world», *PLoS Medicine* 7(8), page e1000333.
- Niraula, S., Seruga, B., Ocana, A., Shao, T., Goldstein, R., Tannock, I. F. et al. (2012), «The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs», *Journal of Clinical Oncology* 30(24), pages 3012 à 3019.
- Nunn, A. S., Fonseca, E. M., Bastos, F. I., Gruskin, S. et Salomon, J. A. (2007), «Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment», *PLoS Medicine* 4(11), page e305.
- Obrist, B., Iteba, N., Lengeler, C., Makemba, A., Mshana, C., Nathan, R. et al. (2007), «Access to health care in contexts of livelihood insecurity: A framework for analysis and action», *PLoS Medicine* 4(10), page e308.
- Office des brevets et des marques des États-Unis (USPTO) (2001), «Final Guidelines for Determining Utility of Gene-Related Inventions», communiqué de presse, 4 janvier 2001.
- Office des brevets et des marques des États-Unis (USPTO) (2018), *New PTAB Studies in AIA Proceedings: Expanded Panels and Trial Outcomes for Orange Book-listed Patents*, voir: [https://www.uspto.gov/sites/default/files/documents/chat\\_with\\_the\\_chief\\_march\\_2018.pdf](https://www.uspto.gov/sites/default/files/documents/chat_with_the_chief_march_2018.pdf).
- Office des brevets et des marques des États-Unis (USPTO) (2019), *Revised Patent Subject Matter Eligibility Guidance*, publié le 7 janvier 2019 et mis à jour le 17 octobre 2019, voir: <https://www.uspto.gov/patent/laws-and-regulations/examination-policy/subject-matter-eligibility>.
- Office de la propriété intellectuelle (IPO) du Royaume-Uni, Patent Informatics Team (2011), *Patent Thickets: An Overview: Subject to Peer Review*, IPO, Newport (Royaume-Uni).

- Olcay, M. et Laing, R. (2005), «Pharmaceutical Tariffs: What is Their Effect on Prices, Protection of Local Industry and Revenue Generation?: Prepared for: The Commission on Intellectual Property Rights, Innovation and Public Health», OMS, Genève.
- Olliaro, P. L., Kuesel, A. C., Halleux, C. M., Sullivan, M. et Reeder, J. C. (2018), «Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years», *PLoS Neglected Tropical Diseases* 12(11), page e0006837.
- Olson, L. M. et Wendling, B. W. (2013), «The Effect of Generic Drug Competition on Generic Drug Prices during the Hatch-Waxman 180-day Exclusivity Period», document de travail n° 317, FTC Bureau of Economics, Washington (D.C.).
- Olson, S. et Berger, A. (2011), *Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Drug Development: Workshop Summary*, National Academies Press, Washington (D.C.).
- O'Neill, J. (2016), «Tackling drug-resistant infections globally: final report and recommendations», The Review on Antimicrobial Resistance, voir: [https://amr-review.org/sites/default/files/160525\\_Final\\_paper\\_with\\_cover.pdf](https://amr-review.org/sites/default/files/160525_Final_paper_with_cover.pdf).
- ONUSIDA (2004), *2004: Rapport sur l'épidémie mondiale de SIDA*, voir: [https://files.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2004/GAR2004\\_fr.pdf](https://files.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2004/GAR2004_fr.pdf).
- ONUSIDA (2006), *La poursuite des droits: Études de cas sur le traitement judiciaire des droits fondamentaux des personnes vivant avec le VIH*, voir: [https://files.unaids.org/en/media/unaids/contentassets/dataimport/pub/report/2006/jc1189-courttingrights\\_fr.pdf](https://files.unaids.org/en/media/unaids/contentassets/dataimport/pub/report/2006/jc1189-courttingrights_fr.pdf).
- ONUSIDA, Organisation mondiale de la Santé (OMS) et Programme des Nations Unies pour le développement (PNUD) (2011), «Tirer parti des flexibilités de l'Accord sur les ADPIC pour améliorer l'accès au traitement du VIH», note de synthèse, ONUSIDA, OMS et PNUD, Genève.
- Organisation de coopération et de développement économiques (OCDE) (2008), *Les prix des médicaments sur un marché global*, OCDE, Paris.
- Organisation de coopération et de développement économiques (OCDE) (2017a), *Panorama de la santé 2017: Les indicateurs de l'OCDE*, OCDE, Paris.
- Organisation de coopération et de développement économiques (OCDE) (2017b), *Tackling Wasteful Spending on Health (Lutter contre le gaspillage dans les systèmes de santé)*, voir: <https://www.oecd.org/els/health-systems/Tackling-Wasteful-Spending-on-Health-Highlights-revised.pdf>.
- Organisation de coopération et de développement économiques (OCDE) (2018), *Pharmaceutical Innovation and Access to Medicines (Innovation pharmaceutique et accès aux médicaments), Études de l'OCDE sur les politiques de santé*, page 143, voir: <http://www.oecd.org/health/pharmaceutical-innovation-and-access-to-medicines-9789264307391-en.htm>.
- Organisation de coopération et de développement économiques (OCDE) et Office de l'Union européenne pour la propriété intellectuelle (EUIPO) (2019), *Trends in Trade in Counterfeit and Pirated Goods (Tendances dans le commerce des contrefaçons et des marchandises pirates)*, Éditions OCDE, Paris.
- Organisation des États des Caraïbes orientales (OECO) (2001), *Pharmaceutical Procurement Service Annual Report 2001*, OECO, Sainte-Lucie.
- Organisation mondiale de la Santé (OMS) (2000), *Rapport sur la santé dans le monde, 2000: Pour un système de santé plus performant*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2001a), *Macroéconomie et santé: investir dans la santé pour le développement économique: rapport de la Commission Macroéconomie et Santé*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2001b), «Drug procurement: The principles for getting it right», *Essential Drugs Monitor*, n° 30, pages 13 à 16.
- Organisation mondiale de la Santé (OMS) (2001c), *Comment élaborer et mettre en œuvre une politique pharmaceutique nationale*, 2<sup>ème</sup> édition, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2003a), «Comment élaborer et mettre en œuvre une politique pharmaceutique nationale?», Perspectives Politiques de l'OMS sur les médicaments, n° 6.
- Organisation mondiale de la Santé (OMS) (2003b), *Medical Device Regulations: Global Overview and Guiding Principles*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2003c), «The Selection and Use of Essential Medicines: Report of the WHO Expert Committee 2002, including the 12th Model List of Essential Medicines (Sélection et utilisation des médicaments essentiels: Rapport du Comité OMS d'experts, 2002, y compris la douzième liste modèle des médicaments essentiels)», Série de rapports techniques, n° 914, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2004), «Accès équitable aux médicaments essentiels: cadre d'action collective», Perspectives politiques de l'OMS sur les médicaments, n° 8, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2005), «Remuneration Guidelines for Non-Voluntary Use of a Patent on Medical Technologies», Health Economics and Drugs TCM Series, n° 18, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2006a), *Santé publique, innovation et droits de propriété intellectuelle: Rapport de la Commission sur les droits de la propriété intellectuelle, l'innovation et la santé publique*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2006b), «WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fortieth Report», Série de rapports techniques, n° 937, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2007a), *Everybody's Business: Strengthening Health Systems to Improve Health Outcomes: WHO's Framework for Action*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2007b), *WHO Model List of Essential Medicines for Children: 1st List, October 2007*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2009a), Comité d'experts de la standardisation biologique, Genève, 19-23 octobre 2009, «Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs)», voir: [https://www.who.int/biologicals/publications/trs/areas/biological\\_therapeutics/TRS\\_977\\_Annex\\_2.pdf?ua=1](https://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf?ua=1).
- Organisation mondiale de la Santé (OMS) (2009b), *Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2010), *Assessment of Medicines Regulatory Systems in Sub-Saharan African Countries: An Overview of Findings from 26 Assessment Reports*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2011a), *Increasing Access to Vaccines Through Technology Transfer and Local Production*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2011b), *Local Production for Access to Medical Products: Developing a Framework to Improve Public Health*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2011c), *Cadre de préparation en cas de grippe pandémique pour l'échange des virus grippaux et l'accès aux vaccins et autres avantages*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2011d), «Rôle de l'OMS dans la lutte contre les produits médicaux de qualité, d'innocuité et d'efficacité incertaines, tels que les produits médicaux de qualité inférieure/faux/faussement étiquetés/falsifiés/contrefaits» (A/SSFFC/WG/3 Rev.1), 17 février 2011.

Organisation mondiale de la Santé (OMS) (2012), *La recherche-développement pour répondre aux besoins sanitaires des pays en développement: renforcement du financement et de la coordination au niveau mondial: Rapport du groupe de travail consultatif d'experts sur le financement et la coordination de la recherche-développement*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2013a), *Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020*, OMS, Genève, voir: [https://apps.who.int/iris/bitstream/handle/10665/94384/9789241506236\\_eng.pdf?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/94384/9789241506236_eng.pdf?sequence=1).

Organisation mondiale de la Santé (OMS) (2013b), *Relevé épidémiologique hebdomadaire* 1(88), pages 1 à 16, voir: <https://www.who.int/wer/2013/wer8801.pdf?ua=1> [www.who.int/immunization\\_delivery/new\\_vaccines/technologies\\_aerosol/fr/](http://www.who.int/immunization_delivery/new_vaccines/technologies_aerosol/fr/).

Organisation mondiale de la Santé (OMS) (2014a), *Access to Antiretroviral Drugs in Low- and Middle-Income Countries*, rapport technique, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2014b), *Dépistage, soins et traitement des personnes infectées par le virus de l'hépatite C: lignes directrices de l'OMS*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2014c), *Hepatitis E Vaccine: Composition, Safety, Immunogenicity and Efficacy, A document prepared for Strategic Advisory Group of Experts on Immunization (SAGE) by the Hepatitis E Vaccine Working Group*, voir: [https://www.who.int/immunization/sage/meetings/2014/october/2\\_HepEvaccsafety\\_immunogenicity\\_efficacy\\_final\\_1Oct2014.pdf](https://www.who.int/immunization/sage/meetings/2014/october/2_HepEvaccsafety_immunogenicity_efficacy_final_1Oct2014.pdf).

Organisation mondiale de la Santé (OMS) (2014d), *Increasing Access to HIV Treatment in Middle-Income Countries: Key Data on Prices, Regulatory Status, Tariffs and the Intellectual Property Situation*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2015a), *Access to New Medicines in Europe: Technical Review of Policy Initiatives and Opportunities for Collaboration and Research*, Bureau régional de l'OMS pour l'Europe, Copenhague.

Organisation mondiale de la Santé (OMS) (2015b), *Health in 2015 from MDGs Millennium Development Goals to SDGs Sustainable Development Goals*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2015c), «The Selection and Use of Essential Medicines: Report of the WHO Expert Committee 2015 (including the 19th WHO Model List of Essential Medicines and the 5th WHO Model List of Essential Medicines for Children)», Série de rapports techniques, n° 994, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2015d), *Trade and Health: Towards Building a National Strategy*, Smith, R., Blouin, C., Mirza, Z., Beyer, P. et Drager, N. (éds), OMS, Genève.

Organisation mondiale de la Santé (OMS) (2015e), *WHO Guideline on Country Pharmaceutical Pricing Policies*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2015f), «WHO Statement on Public Disclosure of Clinical Trial Results», 9 avril 2015, voir: [www.who.int/ictrp/results/reporting/en/](http://www.who.int/ictrp/results/reporting/en/).

Organisation mondiale de la Santé (OMS) (2016a), *Global Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2016b), *The Role of Intellectual Property in Local Production in Developing Countries: Opportunities and Challenges*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2016c), *WHO Treatment Guidelines for Drug-Resistant Tuberculosis: 2016 Update: October 2016 Revision*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2016d), «WHO updates patent information on treatment of Hepatitis C», version en ligne.

Organisation mondiale de la Santé (OMS) (2016e), *S'engager pour la santé et la croissance: Investir dans le personnel de santé: Rapport de la Commission de haut niveau sur l'Emploi en Santé et la Croissance économique*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2017a), *Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline, Including Tuberculosis*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2017b), *Global Atlas of Medical Devices*, WHO Medical Devices Technical Series, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2017c), *Global Hepatitis Report 2017 (Rapport mondial sur l'hépatite, 2017)*, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2017d), *Integrating Neglected Tropical Diseases into Global Health and Development: Fourth WHO Report on Neglected Tropical Diseases*, OMS, Genève, voir: <https://apps.who.int/iris/bitstream/handle/10665/255011/9789241565448-eng.pdf?sequence=1>.

Organisation mondiale de la Santé (OMS) (2017e), «Overall programme review of the global strategy and plan of action on public health, innovation and intellectual property», rapport du groupe spécial d'examen, novembre 2017.

Organisation mondiale de la Santé (OMS) (2017f), «The Selection and Use of Essential Medicines: Report of the WHO Expert Committee 2017 (including the 20th WHO Model List of Essential Medicines and the 6th WHO Model List of Essential Medicines for Children)», Série de rapports techniques, n° 1006, OMS, Genève.

Organisation mondiale de la Santé (OMS) (2017g), *Étude de l'impact socioéconomique et sur la santé publique des produits médicaux de qualité inférieure et falsifiés*, OMS, Genève.

- Organisation mondiale de la Santé (OMS) (2017h), *Together on the Road to Universal Health Coverage: A Call to Action*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2017i), «Transition to New Antiretrovirals», HIV Treatment Policy Brief, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2017j), *Le modèle de cadre réglementaire mondial de l'OMS relatif aux dispositifs médicaux incluant les dispositifs médicaux de diagnostic in vitro*, Série technique sur les dispositifs médicaux, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2017k), *Système mondial de surveillance et de suivi de l'OMS pour les produits médicaux de qualité inférieure et falsifiés*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2017l), «WHO to begin pilot prequalification of biosimilars for cancer treatment», 4 mai 2017.
- Organisation mondiale de la Santé (OMS) (2018a), «Approaches to Seasonal Influenza and Genetic Sequence Data under the PIP Framework», 14 décembre 2018.
- Organisation mondiale de la Santé (OMS) (2018b), *Assessing National Capacity for the Prevention and Control of Noncommunicable Diseases: Report of the 2017 Global Survey*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2018c), *Facilitating Access and Benefit-Sharing (ABS) for Pathogens to Support Public Health: Workshop Report: 11–12 June 2018 Workshop*, septembre 2018, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2018d), *Global Vaccine Action Plan: Monitoring, Evaluation & Accountability: Secretariat Annual Report 2018*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2018e), *Progress Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers in Low- and Middle-income Countries*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2018f), *Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR/RR-TB)*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2018g), *Technical Report: Pricing of Cancer Medicines and Its Impacts: A Comprehensive Technical Report for the World Health Assembly Resolution 70.12: Operative Paragraph 2.9 on Pricing Approaches and Their Impacts on Availability and Affordability of Medicines for the Prevention and Treatment of Cancer*, OMS, Genève, voir: <https://apps.who.int/iris/bitstream/handle/10665/277190/9789241515115-eng.pdf?ua=1>.
- Organisation mondiale de la Santé (OMS) (2018h), *Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV: Interim Guidelines: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2018i), *WHO EML cancer medicines working group (CMWG): report of the meeting 22–23 March 2018, Geneva, Switzerland*, OMS, Genève, voir: <https://apps.who.int/iris/bitstream/handle/10665/272962/WHO-EMP-IAU-2018.03-eng.pdf?sequence=1&isAllowed=y>.
- Organisation mondiale de la Santé (OMS) (2019a), *Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2019b), *Executive Summary: The Selection and Use of Essential Medicines 2019: Report of the 22nd WHO Expert Committee on the Selection and Use of Essential Medicines, 1–5 April 2019*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2019c), *Global Tuberculosis Report 2019 (Rapport sur la tuberculose dans le monde: 2019)*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2019d), *Pandemic Influenza Preparedness Framework: Annual Progress Report 1 January–31 December 2018*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) (2019e), «Universal health coverage (UHC)», 24 janvier 2019.
- Organisation mondiale de la Santé (OMS) (2019f), *WHO Global Report on Traditional and Complementary Medicine*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) et Health Action International (HAI) (2008), *Mesurer les prix, la disponibilité, l'accessibilité financière et les composantes des prix des médicaments*, OMS et HAI, Genève et Amsterdam.
- Organisation mondiale de la Santé (OMS) et Banque internationale pour la reconstruction et le développement / Banque mondiale (2020), *Global Monitoring Report on Financial Protection in Health 2019*, OMS, Genève.
- Organisation mondiale de la Santé (OMS) et ONUSIDA (2000), *Patent situation of HIV/AIDS-related drugs in 80 countries*, voir: <https://www.who.int/3by5/en/patentshivdrugs.pdf>.
- Organisation mondiale de la Santé (OMS) et Organisation mondiale du commerce (OMC) (2002), *Les accords de l'OMC et la santé publique: étude conjointe de l'OMS et du Secrétariat de l'OMC*, OMS et OMC, Genève.
- Organisation mondiale de la Santé (OMS), Market Information for Access to Vaccines (MI4A) et Vaccine Product, Price and Procurement (V3P) de l'OMS (2018), *Global Vaccine Market Report*, voir: [https://www.who.int/immunization/programmes\\_systems/procurement/v3p/platform/module2/MI4A\\_Global\\_Vaccine\\_Market\\_Report.pdf?ua=1](https://www.who.int/immunization/programmes_systems/procurement/v3p/platform/module2/MI4A_Global_Vaccine_Market_Report.pdf?ua=1).
- Organisation mondiale de la Santé (OMS), Bureau régional pour l'Europe (2019), *Can people afford to pay for health care? New evidence on financial protection in Europe*, Bureau régional de l'OMS pour l'Europe, Copenhague.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2001), *Savoirs traditionnels: besoins et attentes en matière de propriété intellectuelle: Rapport de l'OMPI sur les missions d'enquête consacrées à la propriété intellectuelle et aux savoirs traditionnels (1998-1999)*, OMPI, Genève.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2007), *Les 45 recommandations adoptées dans le cadre du Plan d'action de l'OMPI pour le développement*, voir: <https://www.wipo.int/ip-development/fr/agenda/recommendations.html>.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2009), *The Economics of Intellectual Property: Suggestions for Further Research in Developing Countries and Countries with Economies in Transition*, OMPI, Genève.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2011a), *WIPO Patent Search Report on Pandemic Influenza Preparedness (PIP)-Related Patents and Patent Applications*, OMPI, Genève.

- Organisation mondiale de la propriété intellectuelle (OMPI) (2011b), *Rapport sur la propriété intellectuelle dans le monde: Le nouveau visage de l'innovation*, OMPI, Genève.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2014a), *Options relatives à la recherche et l'examen en matière de brevets: Guide sur les politiques*, OMPI, Genève.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2014b), «Patent Pools and Antitrust – A Comparative Analysis», OMPI, Genève.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2015a), *Propriété intellectuelle relative aux ressources génétiques, aux savoirs traditionnels et aux expressions culturelles traditionnelles*, OMPI, Genève.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2015b), *Guide de l'OMPI sur l'utilisation de l'information en matière de brevets*, OMPI, Genève.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2015c), *Rapport sur la propriété intellectuelle dans le monde: Innovations majeures et croissance économique*, OMPI, Genève.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2017a), *Guide de la fixation des savoirs traditionnels*, OMPI, Genève.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2017b), *Questions essentielles sur les exigences de divulgation en matière de brevets concernant les ressources génétiques et les savoirs traditionnels*, OMPI, Genève.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2017c), *Comment protéger et promouvoir votre culture: Guide pratique de la propriété intellectuelle pour les peuples autochtones et les communautés locales*, OMPI, Genève, 2017.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2018), *World Intellectual Property Indicators 2018*, OMPI, Genève.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2019a), *Patent Cooperation Treaty Yearly Review 2019: The International Patent System (Revue annuelle du PCT 2019: Le système international des brevets)*, OMPI, Genève.
- Organisation mondiale de la propriété intellectuelle (OMPI) (2019b), *WIPO Technology Trends 2019: Artificial Intelligence (Tendances technologiques 2019: Intelligence artificielle)*, OMPI, Genève.
- Organisation mondiale du commerce (OMC) (2011), *Rapport sur le commerce mondial 2011: L'OMC et les accords commerciaux préférentiels: de la coexistence à la cohérence*, OMC, Genève.
- Organisation mondiale du commerce (OMC) (2012), *A Handbook on the WTO TRIPS Agreement (Guide concernant l'Accord de l'OMC sur les ADPIC)*, Taubman, A., Wager, H. et Watal, J. (éds), Cambridge University Press, New York.
- Organisation mondiale du commerce (OMC) (2018), *L'intégration du commerce en vue de la réalisation des Objectifs de développement durable*, OMC, Genève.
- Organisation des Nations Unies pour l'éducation, la science et la culture (UNESCO), Comité international de bioéthique (CIB) (2017), *Rapport du CIB sur les mégadonnées et la santé*, SHS/YES/IBC-24/17/3 REV.2, UNESCO, Paris.
- Pagliusi, S., Dennehy, M. et Kim, H. (2018), «Vaccines, inspiring innovation in health», *Vaccine*, n° 36, pages 7430 à 7437.
- Pammolli, F., Magazzini, L. et Riccaboni, M. (2011), «The productivity crisis in pharmaceutical R&D», *Nature Reviews Drug Discovery* 10(6), pages 428 à 438.
- Paris, V. et Belloni, A. (2013), «Value in Pharmaceutical Pricing», Documents de travail sur la santé, n° 63, OCDE, Paris.
- Parsons, L. (2019), «Vertex, NHS England and NICE finally reach agreement for Orkambi», *PMLive*, 24 octobre 2019, voir: [http://www.pmlive.com/pharma\\_news/vertex\\_nhs\\_england\\_and\\_nice\\_finally\\_reach\\_agreement\\_for\\_orkambi\\_1314406?utm\\_source=pmlive&utm\\_medium=email&utm\\_campaign=pmlive\\_daily&](http://www.pmlive.com/pharma_news/vertex_nhs_england_and_nice_finally_reach_agreement_for_orkambi_1314406?utm_source=pmlive&utm_medium=email&utm_campaign=pmlive_daily&)
- Paun, C. (2016), «Skyhigh drug prices made Romania mull patent break», *Politico*, version en ligne, 29 mars 2016.
- Penazzato, M., Lewis, L., Watkins, M., Prabhu, V., Pascual, F., Auton, M. et al. (2018), «Shortening the decade-long gap between adult and paediatric drug formulations: A new framework based on the HIV experience in low- and middle-income countries», *Journal of the International AIDS Society*, n° 21(suppl.1), page e25049.
- Perehudoff, S. K., Toebes, B. et Hogerzeil, H. (2016), «Essential medicines in national constitutions: Progress since 2008», *Health and Human Rights Journal* 18(1), pages 141 à 156.
- Pettitt, D., Arshad, Z., Smith, J., Stanic, T., Holländer, G. et Brindley, D. (2018), «CAR-T cells: A systematic review and mixed-methods analysis of the clinical trial landscape», *Molecular Therapy* 26(2), pages 342 à 353.
- von Philipsborn, P., Steinbeis, F., Bender, M. E., Regmi, S. et Tinnemann, P. (2015), «Poverty-related and neglected diseases: An economic and epidemiological analysis of poverty relatedness and neglect in research and development», *Global Health Action* 8(1), version en ligne, 22 janvier 2015.
- PhRMA, PhRMA Annual Membership Survey 2018, voir: <https://heatinformatics.com/posts/2018-phrma-annual-membership-survey>.
- Prasad, V. et Mailankody, S. (2017), «Research and development spending to bring a single cancer drug to market and revenues after approval», *JAMA Internal Medicine* 177(11), pages 1569 à 1575.
- Pray, L. (2008), «Personalized medicine: Hope or hype?», *Nature Education* 1(1), page 72.
- Price, W. N. et Rai, A. K. (2015), «Are trade secrets delaying biosimilars?», *Science* 348(6231), pages 188 et 189.
- Price, W. N. et Rai, A. K. (2016), «Manufacturing barriers to biologics competition and innovation», *Iowa Law Review* 101(3), pages 1023 à 1063.
- Pricewaterhousecoopers International Ltd (PwC) (2008), *Pharma 2020: Virtual R&D – Which Path Will You Take?*, PwC.
- Programme des Nations Unies pour le développement (PNUD) (2014), *Using Competition Law to Promote Access to Health Technologies: A Guidebook for Low- and Middle-Income Countries*, version en ligne, voir: <http://www.undp.org/content/undp/en/home/librarypage/hiv-aids/using-competition-law-to-promote-access-to-medicine.html>.
- Programme des Nations Unies pour le développement (PNUD) (2017), *Using Competition Law to Promote Access to Medicines and Related Health Technologies in Low- and Middle-Income Countries*, version en ligne, voir: [http://adphealth.org/upload/resource/Competition\\_Law\\_Issue\\_Brief\\_final\\_15Aug.pdf](http://adphealth.org/upload/resource/Competition_Law_Issue_Brief_final_15Aug.pdf).

- Programme des Nations Unies pour l'environnement (PNUE) (2019), *Frontiers 2018/19: Emerging Issues of Environmental Concern*, PNUE, Nairobi, voir: <https://wedocs.unep.org/bitstream/handle/20.500.11822/27538/Frontiers1819.pdf?sequence=1&isAllowed=y>.
- Pulcini, C., Mohrs, S., Beovic, B., Gyssens, I., Theuretzbacher, U. et Cars, O. (2016), «Forgotten antibiotics: A follow-up inventory study in Europe, the USA, Canada and Australia», *International Journal of Antimicrobial Agents* 49(1), pages 98 à 101.
- Quinn, R. (2013), «Rethinking antibiotic research and development: World War II and the penicillin collaborative», *American Journal of Public Health* 103(3), pages 426 à 434.
- Quintilio, W., Kubrusly, F.S., Iourtov, D., Miyaki, C., Sakauchi, M.A., et al. (2009), «Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice», *Vaccine* 27(31), pages 4219 à 4224.
- Rägo, L. et Santoso, B. (2008), «Drug Regulation: History, Present and Future», dans van Boxtel, C. J., Santoso, B. et Edwards, I. R. (éds), *Drug Benefits and Risks: International Textbook of Clinical Pharmacology*, 2<sup>ème</sup> édition, IOS Press, Amsterdam.
- Rao, A. (2011), «New technologies for neglected diseases: Can tax credits help biotechnology companies advance global health?», *Journal of Commercial Biotechnology*, n° 17, pages 290 à 292, voir: <https://paperity.org/pl/76961659/new-technologies-for-neglected-diseases-can-tax-credits-help-biotechnology-companies>.
- Reardon, S. (2014), «Ebola treatments caught in limbo», *Nature* 511(7511), page 520.
- Reátegui Valdiviezo, M. (2016), «Datos de Prueba de Productos Farmacéuticos. Análisis de la Legislación Peruana y Tratados Aplicables», *Revista Derecho & Sociedad*, n° 49, pages 143 à 159, voir: <http://revistas.pucp.edu.pe/index.php/derechoysociedad/article/download/19884/19923>.
- Reich, M. R., Harris, J., Ikegami, N., Maeda, A., Cashin, C., Araujo, E. C., et al. (2016), «Moving towards universal health coverage: Lessons from 11 country studies», *The Lancet* 387(10020), pages 811 à 816.
- Relias Media (2005), «FDA drug approvals jump in 2004», version en ligne, 1<sup>er</sup> mai 2005, voir: <https://www.reliasmedia.com/articles/87040-fda-drug-approvals-jump-in-2004>.
- Renwick, M.J., Simpkin V. et Mossialos, E. (2016), *International and European Initiatives Targeting Innovation in Antibiotic Drug Discovery and Development, The Need for a One Health – One Europe – One World Framework*, Health Policy Series, n° 45.
- Reuters (2016), «Beijing buyers club? China's cancer patients gamble on gray market», *Business Insider*, version en ligne, 25 décembre 2016, voir: <http://static3.businessinsider.com/r-beijing-buyers-club-chinas-cancer-patients-gamble-on-gray-market-2016-12>.
- Reuters (2018), «Impatient patients turn to online 'buyers club' for new drugs», *CNBC*, version en ligne, 3 octobre 2018, voir: <https://www.cnbc.com/2018/10/03/impatient-patients-turn-to-online-buyers-club-for-new-drugs.html>.
- Ridley, D. B. et Régnier, S. A. (2016), «The commercial market for priority review vouchers», *Health Affairs* 35(5), pages 776 à 783.
- Rietveld, H. (2008), «A New Class of Malaria Drugs: The Coartem Breakthrough from Novartis and its Chinese Partners», présentation PowerPoint faite au Workshop on Access and Benefit Sharing (atelier sur l'accès et le partage des avantages), 26 mai 2008, Bonn.
- Robertson, J., Forte, G., Trapsida, J.-M. et Hill, S. (2009), «What essential medicines for children are on the shelf?», *Bulletin de l'Organisation mondiale de la Santé* 87(3), pages 231 à 237.
- Rodríguez, P.C., Rodríguez, G., González, G. et Lage, A. (2010), «Clinical Development and Perspectives of CIMAvax EGF, Cuban Vaccine for Non-small-cell Lung Cancer Therapy», *MEDICC Review* 12(1), pages 17 à 23.
- Roger, S. D. et Goldsmith, D. (2008), «Biosimilars: It's not as simple as cost alone», *Journal of Clinical Pharmacy and Therapeutics* 33(5), pages 459 à 464.
- Rosenfeld, L. (2002), «Insulin: discovery and controversy», *Clinical Chemistry* 48(12), pages 2270 à 2288.
- Roth, V. J. (2012), «Will FDA data exclusivity make biologic patents passé?», *Santa Clara High Technology Law Journal* 29(2), pages 249 à 304.
- Röttingen, J.-A., Chamas, C., Goyal, L. C., Harb, H., Lagrada, L. et Mayosi, B. M. (2012), «Securing the public good of health research and development for developing countries», *Bulletin de l'Organisation mondiale de la Santé* 90(5), pages 398 à 400.
- Roughead, E. E., Kim, D. S., Ong, B. et Kemp-Casey, A. (2018), «Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price», *South-East Asia Journal of Public Health de l'OMS* 7(2), septembre 2018, pages 99 à 106.
- Roughead, L., Semple, S. et Rosenfeld, E. (2013), *Literature Review: Medication Safety in Australia*, Australian Commission on Quality and Safety in Health Care, Darlinghurst (New South Wales).
- Sag, M. (2009), «Copyright and copy-reliant technology», *Northwestern University Law Review* 103(4), pages 1607 à 1682.
- Sagonowsky, E. (2017), «Promising Ebola vaccines from Merck, Johnson & Johnson win BARDA funding», *FiercePharma*, version en ligne, 2 octobre 2017, voir: <https://www.fiercepharma.com/vaccines/promising-ebola-vaccines-from-merck-j-j-win-barda-funding>.
- Sagonowsky, E. (2018), «Merck Starts Rolling FDA Submission for Its Ebola Vaccine, Aiming to Finish Next Year», *FiercePharma*, version en ligne, 15 novembre 2018, voir: <https://www.fiercepharma.com/vaccines/merck-starts-fda-submission-for-ebola-vaccine-aiming-to-finish-next-year>.
- El Said, M. K. (2010), *Public Health Related Trips-Plus Provisions in Bilateral Trade Agreements: A Policy Guide for Negotiators and Implementers in the WHO Eastern Mediterranean Region*, OMS et CICDD, Genève.
- Sampat, B. N. (2015), «Intellectual Property Rights and Pharmaceuticals: The Case of Antibiotics», Document de recherche économique n° 26, OMPI, Genève.
- Sampat, B. N. et Shadlen, K. (2016), *The Effects of Restrictions on Secondary Pharmaceutical Patents: Brazil and India in Comparative Perspective*, voir: <http://www.hbs.edu/faculty/Lists/Events/Attachments/1124/Secondary%20Pharma.pdf>.
- Sanchez-Luna, M., Burgos-Pol, R., Oyagüez, I., Figueras-Aloy, J., Sánchez-Solis, M., Martínón-Torres, F. et al. (2017), «Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: Update based on the clinical evidence in Spain», *BMC Infectious Diseases* 17(1), page 687.
- Sarbacker, G. B. et Urteaga, E. M. (2016), «Adherence to Insulin Therapy», *Diabetes Spectrum* 29(3), pages 166 à 170.



- Savedoff, W. D. (2011), «Governance in the Health Sector: A Strategy for Measuring Determinants and Performance», Policy Research Working Paper, n° 5655, Banque mondiale, Washington (D.C.).
- Scaria, A. G. et Mammen, K. S. (2018), «Non-Traditional Marks in the Pharmaceutical Sector: Non-Traditional Barriers to Access to Medicine?» dans Calboli, I. et Senftleben, M. (éds), *The Protection of Non-Traditional Trademarks: Critical Perspectives*, Oxford University Press, Oxford.
- Schafer, J., Tapella, M. et Kantarelis, T. (2016), «Biosimilars: Why deep discounts may become the dominant paradigm», *Pharmaceutical Commerce*, version en ligne, 22 février 2016.
- Schell, J. (2013), «*Neurim*: a new definition of 'product' in supplementary protection certificates?», *Journal of Intellectual Property Law & Practice* 8(9), pages 723 à 728, voir: <https://doi.org/10.1093/jiplp/jpt130>.
- Scherer, F. M. et Watal, J. (2002), «Post-TRIPS options for access to patented medicines in developing nations», *Journal of International Economic Law* 5(4), pages 913 à 939.
- Schmucker, C., Schell, L. K., Portalupi, S., Oeller, P., Cabrera, L., Bassler, D. et al. (2014), «Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries», *PLoS ONE*, n° 9, page e114023.
- Schuhmacher, A., Gassman, O. et Hinder, M. (2016), «Changing R&D models in research-based pharmaceutical companies», *Journal of Translational Medicine* 14(1), page 105.
- Schuhmacher, A., Gassman, O., McCracken, N. et Hinder, M. (2018), «Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?», *Journal of Translational Medicine*, n° 16, page 119.
- Schwieterman, W. D. (2006), «Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective», *Drug Discovery Today* 11(19–20), pages 945 à 951.
- Scutti, S. (2018), «Gene therapy for rare retinal disorder to cost \$425,000 per eye», *CNN*, version en ligne, 3 janvier 2018, voir: <https://www.cnn.com/2018/01/03/health/luxturna-price-blindness-drug-bn/index.html>.
- Shapiro, C. (2001), «Navigating the Patent Thicket: Cross Licences, Patent Pools and Standard Setting», dans Jaffe, A. B., Lerner, J. et Stern, S. (éds), *Innovation Policy and the Economy*, vol. 1, MIT Press, Cambridge (Massachusetts).
- Shcherbakova, N., Shepherd, M., Lawson, K. et Richards, K. (2011), «The role of authorized generics in the prescription drug marketplace», *Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector* n° 8, pages 28 à 40.
- Shedden, K. (2018), présentation faite au Symposium technique OMS-OMPI-OMC sur les objectifs de développement durable: des technologies novatrices pour promouvoir vie saine et bien-être, 26 février 2018, Genève.
- Shum, T., Kruse, R. L. et Rooney, C. M. (2018), «Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities», *Expert Opinion on Biological Therapy* 18(6), pages 653 à 664.
- Silverman, E. (2017a), «Netherlands health minister threatens compulsory licenses over 'absurd prices'», *STAT News*, voir: <https://www.statnews.com/pharmalot/2017/11/27/netherlands-patents-compulsory-licenses-vertex/>.
- Silverman, E. (2017b), «Under pressure, Gilead expands Sovaldi licensing deal to four middle-income countries», *STAT News*, voir: <https://www.statnews.com/pharmalot/2017/08/24/gilead-sovaldi-malaysia-ukraine/>.
- Simon-Kucher & Partners (2016), *Payers' Price & Market Access Policies Supporting a Sustainable Biosimilar Medicines Market: Final Report*, Simon-Kucher & Partners, Bonn.
- Son, K., Lopert, R., Gleeson, D. et Lee, T. (2018), «Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States», *Globalization and Health* 14(101), voir: <https://doi.org/10.1186/s12992-018-0423-0>.
- Srivastava, R. K. et More, A. T. (2010), «Some aesthetic considerations for over the-counter (OTC) pharmaceutical products», *International Journal of Biotechnology* 11(3-4), pages 267 à 283.
- Stanaway, J. D., Afshin, A., Gakidou, E., Lim, S. S., Abate, D., Abate, K. H., et al. (2018), «Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017», *The Lancet* 392(10159), pages 1923 à 1994.
- Stenberg, K., Hanssen, O., Edejer, T. T., Bertram, M., Brindley, C., Meshreky, A. et al. (2017), «Financing transformative health systems towards achievement of the health Sustainable Development Goals: A model for projected resource needs in 67 low-income and middle-income countries», *The Lancet Global Health* 5(9), pages e875 à e887.
- Stevens, A. J. et Effort, A. E. (2008), «Using academic license agreements to promote global social responsibility», *Les Nouvelles*, n° 43, page 85.
- Stevens, A. J., Jensen, J. J., Wyller, K., Kilgore, P. C., Chattergee, S. et Rohrbaugh, M. L. (2011), «The role of public-sector research in the discovery of drugs and vaccines», *New England Journal of Medicine* 364(6), pages 535 à 541.
- Sussex, J., Feng, Y., Mestre-Ferrandiz, J., et al. (2016), «Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom», *BMC Medicine* 14(32), version en ligne, 25 février 2016.
- Tängdén, T., Pulcini, C., Aagaard, H., Balasegaram, M., et al. (2018), «Unavailability of old antibiotics threatens effective treatment for common bacterial infections», *The Lancet Infectious Diseases* 18(3), pages 242 à 244.
- Tay-Teo, K., Ilbawi, A. et Hill, S. R. (2019), «Comparison of sales income and research and development costs for FDA-approved cancer drugs sold by originator drug companies», *JAMA Network Open* 2(1), page e186875.
- Taylor, C. T. et Silberston, Z. A. (1973), *The Economic Impact of the Patent System: A Study of the British Experience*, Cambridge University Press, Cambridge.
- Temin, P. (1979), «Technology, regulation, and market structure in the modern pharmaceutical industry», *The Bell Journal of Economics* 10(2), pages 429 à 446.
- Tenn, S. et Wendling, B. W. (2014), «Entry threats and pricing in the generic drug industry», *Review of Economics and Statistics*, n° 96, pages 214 à 228.

- Thomas, J. R. (2014), *The Role of Patents and Regulatory Exclusivities in Pharmaceutical Innovation*, Congressional Research Service, Washington (D.C.).
- Thomas, J. R. (2015), *Pharmaceutical Patent Law*, 3<sup>ème</sup> édition, Bloomberg BNA, Arlington (Virginie).
- Todd, Matthew (2010), «A Summary of What Is Needed Right Now», The Synaptic Leap's Synthetic Praziquantel Project, voir: <http://www.thesynapticleap.org/node/286>.
- Toebes, B., Ferguson, R., Markovic, M. M. et Nnamuchi, O. (éds) (2014), *The Right to Health, A Multi-Country Study of Law, Policy and Practice*, Asser Press, La Haye.
- Toland, A. E., Forman, A., Couch, F. J., Culver, J. O., et al. pour le compte du BIC Steering Committee (2018), «Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices», *npj Genomic Medicine* 3(7), voir:10.1038/s41525-018-0046-7.
- Tomas Gomez-Arostegui, H. (2010), «Prospective Compensation in Lieu of a Final Injunction in Patent and Copyright Cases», *Fordham Law Review* 78(4), voir: <http://ir.lawnet.fordham.edu/flr/vol78/iss4/2>.
- Topol, E. J. (2019), «High-performance medicine: The convergence of human and artificial intelligence», *Nature Medicine*, n° 25, pages 44 à 56.
- Tripathi, P., Rawat, G., Yadav, S. et Saxena, R. K. (2015), «Shikimic acid, a base compound for the formulation of swine/avian flu drug: statistical optimization, fed-batch and scale up studies along with its application as an antibacterial agent», *Antonie van Leeuwenhoek: Journal of Microbiology*, n° 107, pages 419 à 431.
- Trippe, A. (2015), *Guidelines for Preparing Patent Landscape Reports*, OMPI, Genève.
- Union africaine, «African Union Ministers of Health adopt treaty for the establishment of the African Medicines Agency Treaty to be submitted to the Specialised Technical Committee on Justice and Legal Affairs later on this year», communiqué de presse, 20 mai 2018, voir: <https://au.int/en/pressreleases/20180520/african-union-ministers-health-adopt-treaty-establishment-african-medicines>.
- UNITAID (2014a), *A Review of the Bedaquiline Patent Landscape: A Scoping Report*, secrétariat d'UNITAID, Genève.
- UNITAID (2014b), *HIV/AIDS Diagnostics Technology Landscape*, 4<sup>ème</sup> édition, voir: [https://unitaid.org/assets/UNITAID-HIV\\_Diagnostic\\_Landscape-4th\\_edition.pdf](https://unitaid.org/assets/UNITAID-HIV_Diagnostic_Landscape-4th_edition.pdf).
- UNITAID (2017), *Tuberculosis Diagnostics Technology Landscape*, 5<sup>ème</sup> édition, mai 2017, voir: <https://unitaid.org/assets/2017-Unitaid-TB-Diagnostics-Technology-Landscape.pdf>.
- UNITAID et Medicines Patent Pool (2015), *Patents and Licences on Antiretrovirals: A Snapshot*, secrétariat d'UNITAID, Genève.
- Uzuner, H., Bauer, R., Fan, T. P., Guo, D. A., Diaz, A., El-Nezami, H. et al. (2012), «Traditional Chinese medicine research in the post-genomic era: Good practice, priorities, challenges and opportunities», *Journal of Ethnopharmacology* 140(3), pages 458 à 468.
- van den Ham, R., Bero, L. et Laing, R. (2011), *The World Medicines Situation 2011: Selection of Essential Medicines*, OMS, Genève.
- van den Heuvel, R., Stirling, C., Kapadia, A., Zhou, J. (2018), *Medical Devices 2030: Making a power play to avoid the commodity trap*, KPMG, voir: <https://institutes.kpmg.us/content/dam/institutes/en/healthcare-life-sciences/pdfs/2018/medical-devices-2030.pdf>.
- van Luijn, J. C., Gribnau, F. W. et Leufkens, H. G. (2010), «Superior efficacy of new medicines?», *European Journal of Clinical Pharmacology* 66(5), pages 445 à 448.
- Viergever, R. F. et Hendriks, T. C. C. (2016), «The 10 largest public and philanthropic funders of health research in the world: What they fund and how they distribute their funds», *Health Research Policy and Systems*, n° 14, page 12.
- Vitry, A. I., Shin, N. H. et Vitre, P. (2013), «Assessment of the therapeutic value of new medicines marketed in Australia», *Journal of Pharmaceutical Policy and Practice* 6(1), page 2.
- Vivot, A., Jacot, J., Zeitoun, J.-D., Ravaut, P., Crequit, P. et Porcher, R. (2017), «Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015», *Annals of Oncology*, n° 28, pages 1111 à 1116.
- Vogler, S. et Schneider, P. (2019), «Medicine Price Data Sources», dans *Medicine Price Surveys, Analyses and Comparisons*, Vogler, S. (éd.), Academic Press, Londres.
- Vogler, S., Zimmermann, N., Habl, C., Piessnegger, J. et Bucsics, A. (2012), «Discounts and rebates granted to public payers for medicines in European countries», *Southern Med Review* 5(1), pages 38 à 46.
- Von Der Ropp, A. et Taubman, T. (2006), «Bioethics and patent law: The case of Myriad», *Magazine de l'OMPI*, n° 4, pages 8 et 9.
- Vondeling, G. T., Cao, Q., Postma, M. J. et Rozenbaum, M. A. (2018), «The impact of patent expiry on drug prices: A systematic literature review», *Applied Health Economics and Health Policy* 16(5), pages 653 à 660.
- Wang, H., Sun, Q., Vitry, A. et Nguyen, T. A. (2017), «Availability, price, and affordability of selected essential medicines for chronic diseases in 11 countries of the Asia Pacific Region: A secondary analysis», *Asia Pacific Journal of Public Health* 29(4), pages 268 à 277.
- Wang, H., Vinyals Torres, L. et Travis, P. (2018), «Catastrophic health expenditure and financial protection in eight countries in the WHO South-East Asia Region», *Bulletin de l'Organisation mondiale de la Santé* 96(9), pages 610 à 620E.
- Ward, A. (2015), «Medical Research Council faces budget crunch from 'patent cliff'», *Financial Times*, version en ligne, 16 août 2015, voir: <https://www.ft.com/content/bdd435c6-4293-11e5-b98b-87c7270955cf>.
- Wasserman, E. (2016), «Takeda loses again to Hikma in gout drug patent battle», *FiercePharma*, version en ligne, 24 mai 2016.
- Watal, J. (2001), «Workshop on Differential Pricing and Financing of Essential Drugs: Background Note Prepared by Jayashree Watal, Consultant to the WTO Secretariat», OMC, Genève.
- Watal, J. et Dai, R. (2019), «Product Patents and Access to Innovative Medicines in a Post-TRIPS-Era», document de travail ERSD-2019-05, OMC, Genève.
- Weires, R. (2019), «Recent advances in biologics manufacturing diminish the importance of trade secrets: a response to Price and Rai», *Written Description*, 4 mars 2019.

- Welch, A. R. (2016a), «The Norwegian biosimilar phenomenon: From biosimilar to 'biogeneric'», *Biosimilar Development*, version en ligne, 26 juillet 2016.
- Welch, A. R. (2016b), «What to know about emerging market biosimilar pathways», *Biosimilar Development*, version en ligne, 24 juin 2016.
- Wendland, W. et Jiao, F. (2018), «Intellectual Property Rights and Traditional Medical Knowledge in Africa: Issues and Development», dans Wambebe, C. (éd.), *African Indigenous Medical Knowledge and Human Health: Research, Development, and Delivery*, CRC Press, Boca Raton (Floride).
- West, D. M., Villasenor, J. et Schneider, J. (2017), *Private Sector Investment in Global Health R&D: Spending Levels, Barriers and Opportunities*, The Brookings Institution, Washington (D.C.).
- Wieseler, B., McGauran, N. et Kaiser, T. (2019), «New drugs: where did we go wrong and what can we do better?», *BMJ*, n° 366, page 14340.
- Williams, H. L. (2017), «How do patents affect research investments?», *Annual Review of Economics*, n° 9, pages 441 à 469.
- Wingrove, J. (2019), «SPC waiver may drive innovator investment in secondary patents and litigation», *Patent Strategy*, version en ligne, 9 mai 2019, voir: <https://patentstrategy.managingip.com/Articles/38>.
- Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., et al. (2017), «Essential medicines for universal health coverage», *The Lancet* 389(10067): 403 à 476.
- Workman, P., Draetta, G. F., Schellens, J. H. M. et Bernards, R. (2017), «How much longer will we put up with \$100,000 cancer drugs?», *Cell* 168(4), pages 579 à 583.
- Wouters, O. J., Kanavos, P. G. et McKee, M. (2017), «Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes and Spending», *Millbank Quarterly* 95(3), pages 554 à 601.
- Wouters, O. J., Sandberg, D. M., Pillay, A. et Kanavos, P. G. (2019), «The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period», *Social Science & Medicine*, n° 220, pages 362 à 370.
- Yadav, P. (2010), *Differential Pricing for Pharmaceuticals: Review of Current Knowledge, New Findings and Ideas for Action: A study conducted for the UK Department for International Development (DFID)*, Zaragoza.
- Yamane, H. (2011), *Interpreting TRIPS: Globalisation of Intellectual Property Rights and Access to Medicines*, Hart Publishing, Oxford et Portland (Oregon).
- Young, R., Bekele, T., Gunn, A., Chapman, N., Chowdhary, V., Corrigan, K. et al. (2018), «Developing new health technologies for neglected diseases: A pipeline portfolio review and cost model», *Gates Open Research*, n° 2, page 23.
- Zain, S. (2014), «Antitrust Liability for Maintaining Baseless Litigation», *Santa Clara Law Review* 54(3), pages 729 à 759, voir: <http://digitalcommons.law.scu.edu/lawreview/vol54/iss3/5>.
- Ziegler, N. Gassmann, O. et Friesike, S. (2014), «Why do firms give away their patents for free?», *World Patent Information*, n° 37, pages 19 à 25.